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Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the 
world, and 5-Fluorouracil (5-FU) based regimens are chiefly employed for its 
therapy. Modern regimens, based on 5-FU in combination with other drugs have 
improved the response rates in the terminal CRCs to ~50%. However, a lack of 
molecular understanding of the cellular response process upon 5-FU treatment has 
stalled development of more improved therapies. Here, it behooves to study the 
mechanistic aspects of the complex, but coordinated signaling pathway that gets 
activated upon DNA damage, the DNA damage response (DDR). Current focus is on 
understanding the action of chemotherapeutic drugs, especially nucleoside analogs 
like 5-FU, in the context of DDR to find molecular targets to enhance their efficacies.  
In the present study, we focus on understanding the molecular basis of 5-FU based 
neoadjuvant therapy and finding novel targets for improving the response rates in 
CRC patients. We find that 5-FU pretreatment radiosensitizes CRC cell lines to 
neocarzinostatin (NCS) and leads to persistent γ-H2AX, a marker for DNA double 
strand breaks. We further show that 5-FU reduces the ability of cells to perform 
homologous recombination repair (HRR) but not non-homologous end joining 
(NHEJ), which points towards HRR being the underlying molecular mechanism of 
radiosensitizaztion by 5-FU. The use of B02, an inhibitor of HRR also shows 
persistent γ-H2AX, further strengthening our hypothesis.  
Our subsequent investigations rule out impaired recruitment of repair proteins as the 
possible cause of 5-FU induced HRR reduction. On the other hand, ribonucleotide 
supplementation reduces 5-FU and NCS induced DNA damage suggesting that 
nucleotide pool disruption is a possible cause of 5-FU induced HRR reduction. Also 
the Thymidylate synthetase (TS) inhibitor raltitrexed does not synergize with NCS. 
Interestingly, we find complementary lethality between TS depletion and 5-FU; 
however, TS depletion using siRNA also does not synergize with NCS. We, 
therefore, postulate that 5-FU induced TS inhibition and DNA damage both are 
essential for reducing the HRR.  
 
We also find that Gemcitabine, another nucleoside analog, does not show any 
synergism with NCS, which render it unsuitable for studying DDR in SW480 cells. 
Interestingly, Ribonucleotide Reductase M2 (RRM2) depletion and hydroxyurea 
treatment also does not lead to synergism with NCS. Therefore, we conclude that 
Ribonucleotide reductase inhibition cannot synergize or affect the HRR in SW480 
cells. Further, MK2 depletion, which rescues cells from gemcitabine-induced DNA 
damage does not exert such an effect in 5-FU treated cells, indicating that MK2 does 
not play any significant part in 5-FU induced DNA damage.  
In conclusion, our results strongly suggest that the molecular reason for 5-FU 
induced radiosensitization is a reduction in the cellular ability to carry out HRR. This 
leads us to postulate that HRR inhibitors like B02 can be used in future regimens to 
overcome 5-FU resistant colorectal cancers. 
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1 Introduction 
1.1 Colorectal cancer and its therapy 
Cancer is classified as a disease characterized by uncontrolled cell growth. It has 
been attributed to 8.2 million deaths in 2012 by WHO and occurs in almost all the 
tissues in the body. The most common cancer staging system is known as TNM 
(Tumors/Nodes/Metastasis), which classifies cancers from stage 0 to stage IV with 
stage 0 confined to mucosa while stage IV represents distant metastasis.      
Colorectal cancer (CRC) is the second most common cancer in the world and 
accounts for around 600,000 deaths every year (Jemal et al., 2011) As with other 
cancers, early diagnosis of the cancer is key to a better overall survival; response 
rates in stage I are more than 90% as compared to a dismal 10% in stage IV 
(Longley et al., 2003). 
 
1.2 Genesis of colorectal cancer  
It is difficult to predict the exact reason for tumor development but there are certain 
genetic and physiological changes that can forecast the onset and progression of 
tumor. Firstly, certain germline mutations are known to increase the risk of acquiring 
CRC, chief among these is germline mutation in mismatch repair genes, MLH1 and 
MLH2; persons with these mutations have an 80% chance of developing hereditary 
nonpolyposis colon cancer (HNPCC). Similarly, germline inactivation of both the 
alleles of a base excision repair gene mutY homologue (MUTYH) is associated with 
definite probability of developing CRC (Rustgi, 2007). 
Not all the mutations described in CRC are hereditary or germline. Instead most of 
the mutations are acquired progressively and correspond to the growth of tumor from 
a small adenoma to metastatic adenocarcinoma. One of the first genes that gets 
affected is adenomatous polyposis coli (APC) (Fodde, 2002). APC normally forms a 
complex with glycogen synthase kinase 3-beta (GSK3-β) and axin to form a β-
catenin degradation complex. In the absence of APC, this complex is inactive and 
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therefore β-catenin is not degraded. β-catenin is the major canonical effector of Wnt 
signaling and the lack of APC constitutively activates the Wnt signaling (Najdi et al., 
2011).  
The second major mutation in the progression of CRC occurs in TP53 (Valentini et 
al., 2003). The p53 is a tumor suppressor that performs many functions including cell 
cycle arrest and/or apoptosis in response to DNA damage. Mutation in this gene is 
pivotal in the transition of adenomas to invasive carcinomas. 
A third major mutation happens in TGF-β, whose inactivation uncouples the growth 
inhibitory signals and the tumor growth (Derynck et al., 2001). This further aids in the 
transition from adenoma to carcinoma. Apart from these there are several other 
mutations like KRAS, PTEN, BRAF which contribute to the growth and progression 
of the CRC from a benign adenoma to malignant adenocarcinoma (Markman et al., 
2010) (Molinari and Frattini, 2013).     
 
1.3 Neoadjuvant and adjuvant therapy 
The therapeutic regimen for CRC is largely guided by the stage at which it is 
diagnosed. Wherever feasible the cornerstone of treatment is surgical removal of the 
tumor. This is followed by chemoradiotherapy to prevent any relapse of the tumor. 
Recently, a chemoradiotherapy regimen has also been added and is known as 
Neoadjuvant therapy (Fleming et al., 2011). 
1.3.1 Neoadjuvant therapy 
Neoadjuvant therapy constitutes the pre-operative regimen and is mainly 
administered to sensitize tumor cells towards chemotherapy. In general, the patients 
are given 5-Fluorouracil (5-FU) alone or in combination with other 
chemotherapeutics and radiation. This regimen was introduced in early 2000’s after 
studies showed an increased 5 year survival rates in patients (Sauer et al., 2004). 
However, similar studies conducted independently elsewhere did not give such 
promising results (Park et al., 2011). Of late however, neoadjuvant therapy has 
come to be associated with several advantages:  
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(i) Size of the tumors can be reduced which may help the surgical procedure,  
(ii) Response of individual patients towards the chemotherapeutics can be 
gauged and tailored regimens can be created with improved response 
rates.   
1.3.2 Adjuvant therapy 
Adjuvant therapy is the chemoradiotherapy regimen administered post-surgery. 
Here, insights gained during neoadjuvant therapy are used to devise the regimen. 
The goal of the adjuvant therapy is to prevent the tumor relapse. 5-FU is the drug of 
choice for the treatment of CRC and is combined with other drugs in the adjuvant 
therapy. Popular regimens include combination of folinic acid, 5-FU and oxaliplatin 
(FOLFOX); folinic acid, 5-FU and irinotecan (FOLFIRI), combination choices also 
vary with the location. These and several other combinations are listed in the Table 
1.1 along with typical doses. 
 
Table 1.1 5-FU based chemotherapy regimens 













5-FU+Oxaliplatin 2250+85 FUOX 
Capecitabine +Oxaliplatin 1000+130 XELOX 
http://emedicine.medscape.com/article/2005487 
1.4 Nucleoside analogs in cancer therapy 
Nucleoside analogs have been used in cancer treatment for over five decades. They 
are classified as purine and pyrimidine nucleoside analogs and each one has its own 
unique way of inducing DNA damage and apoptosis. 
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1.4.1 Pyrimidine nucleoside analogs 
Cytarabine (ara-C) was the first nucleoside analog developed and is still used for 
treating acute myelogenous leukemia (AML) (Johnson et al., 2001). Following 
phosphorylation, it competes with dCTP for incorporation into DNA, once 
incorporated it causes chain termination and replication fork stalls (Townsend and 
Cheng, 1987). A closely related analog called gemcitabine is also used in clinics for 
treating a variety of solid tumors (see ahead). Interestingly, even nucleoside analogs 
having a β-L-configuration are damaging to DNA. For instance, troxacitabine has 
been reported to passively diffuse into cells and get phosphorylated resulting in 
replication fork stalls (Grove and Cheng, 1996). Another pyrimidine analog, CNDAC 
produces DNA double strand breaks but unlike others leads to G2 arrest in cells. 
The oral form of this drug, sapacitabine is currently in phase 3 trials for AML therapy 
(Kantarjian et al., 2012).  
1.4.2 Purine nucleoside analogs 
The purine nucleoside analogs were also developed around the same time as the 
pyrimdine analogs. Fludarabine functions by affecting the dNTP pools and inhibiting 
the DNA polymerase (Randerath et al., 1983). It is used for treating chronic 
lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma. Another purine analog, 
Cladribine functions by depleting ATP and NAD in cells (Carson et al., 1986) leading 
to apoptosis. Further, clofarabine also gets incorporated into DNA and causes 
disruption of the nucleotide pools, however it is more stable than others causing 
greater damage (Carson et al., 1992). 
1.4.3 5-Fluorouracil 
As already mentioned, 5-FU is a nucleoside analogue that is most commonly used to 
treat CRC. It was discovered in 1957 and has been in use for almost five decades 
now as an anti-cancer drug (Heidelberger et al., 1957). In 1989, continuous venous 
infusions were accepted as a standard therapy for colorectal cancer (Lokich et al., 
1989).  Through this mode of administration the response rates are around 10-15% 
but generally it is given in combination with other drugs that increase response rates 
to 40-50% (Longley et al., 2003).  
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Mechanism of action 
5-FU enters the cells by facilitated diffusion and is then progressively metabolized 
into FUTP, FdUTP and FdUMP (Figure 1-1). FUTP gets incorporated into RNA 
causing RNA damage and FdUTP in DNA causing DNA damage, while FdUMP 
forms a covalent bond with thymidylate synthetase (TS) and inhibits its action 
(Longley et al., 2003). TS inhibition causes disruption of nucleotide pools affecting 
the DNA synthesis. FUTP inhibits processing of the pre-rRNA and also prevents post 
translational modifications of tRNA (Ghoshal and Jacob, 1994). Misincorporation of 
5-FU in the DNA leads to lesions that are recognized by the mismatch repair system 
(MMR) system or the base excision repair (BER) system (Wyatt and Wilson, 2009)  
 
 
Figure 1.1 Mechanism of 5-FU action. 
5-FU enters the cell using facilitated diffusion and is metabolized into, FdUMP that inhibits 
TS; FdUTP that gets misicorporated in DNA causing DNA damage; FUTP, that gets 
misicorporated in RNA casuing RNA damage and; DHFU that does not have any anti-cancer 
effect. Figure modified from (Longley et al., 2003). Chemical structure of 5-FU obtained from 
Sellechkem.com.  
  
Inhibition of Thymidylate synthetase 
TS catalyzes the conversion of dUMP to dTMP and is the only source of de novo 
synthesis of thymidylate in the cell (Touroutoglou and Pazdur, 1996). TS functions 
as a dimer and binds to dUMP and 5, 10 methylene tetrahydrofolate, which acts as 
the methyl group donor (Figure 1-2). FdUMP competes with dUMP for the active site 
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on TS and forms a covalent ternary complex with 5, 10 methylene tetrahydrofolate, 
which is very stable (Carreras and Santi, 1995; Longley et al., 2003). The ternary 
complex with FdUMP was shown to have 13Kcal/mol less binding energy than 
dUMP indicating the stability of the complex over dUMP containing complex 
(Kaiyawet et al., 2013).  The end result of this stable complex formation is the 
sequestration of TS and hence the disruption of the nucleotide pools.  
 
Figure 1.2 TS inhibition by FdUMP. 
TS dimer binds to dUMP and 5, 10 methylene tetrahyrofolate (MTHF) to catalyze conversion 
to dTMP. 5-FU metabolite. FdUMP competes with dUMP and inhibits the catalytic 
conversion to dTMP. Figure modified from (Longley et al., 2003). 
 
Clinical use and toxicity 
It has been reported that 1 in 3 patients receiving 5-FU encounters serious life 
threatening side effects. These include decrease in white blood cells, infections, 
nausea, vomiting etc. About 1-7% patients, receiving 5-FU also exhibit cardiac 
symptoms like myocardial infarctions (Alter et al., 2006).   
1.4.4 Gemcitabine  
Gemcitabine (2’, 2’-difluoro-2’-deoxycytidine; dFdC) was synthesized in 1980, as an 
anti-viral drug (Hertel et al., 1990) but was later shown to have anti-tumor activity. It 
 Introduction  7 
is used in therapy of breast cancer, pancreatic cancer, and bladder cancer either as 
a single agent or in combination with other drugs. It is a radiosensitizer and induces 
an S phase arrest (Shewach and Lawrence, 1996b)  
Mechanism of action 
Upon activation by deoxycytidine kinase, gemcitabine is incorporated into DNA, 
causing DNA damage (Figure 1-3). When two dFdC molecules are added next to 
each other in the newly synthesized DNA strands, the DNA polymerase cannot 
elongate the DNA strand any further and therefore the replication stalls (Sampath et 
al., 2002; Shi et al., 2001). The stalled replication is irreversible, and is one of the 
reasons for its anti-cancer activity. Apart from replication fork stall, gemcitabine also 
inhibits the enzyme ribonucleotide reductase (Pereira et al., 2004). This inhibition 
causes a disruption in nucleotide pools which affects the new DNA synthesis. It is 
administered intravenously in combination with carboliplatin or other drugs, but there 
are a myriad of side effects of gemcitabine like pulmonary toxicity, diarrhea, 
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Figure 1.3 Mechanism of gemcitabine activation and misincorporation into DNA. 
Gemcitabine (dFdC) enters the cell and is activated by deoxycytidine kinase (DCK) followed 
by further phosphorylations to form dFdCDP, which inhibits ribonucleotide reductase, and 
dFdCTP which gets incorporated in DNA causing chain termination. Figure modified from 
(Resende et al., 2007). Gemcitabine structure was obtained from 
http://www.chemspider.com/ImageView.aspx?id=54753.  
 
1.5 NCS and gamma radiation  
Neocarzinostatin is a radiomimetic secreted by Streptomyces neocarzinostaticus. It 
is composed of a protein and an enediyne component (Figure 1-4). The protein 
component is proposed to stabilize the enediyene component, and improve the half-
life of the molecule (Goldberg, 1991). However, another view is that the protein 
component guides the enediyene component in to the cell (Kappen et al., 1980). 
This view is based on high concentration of the protein component around the cell 
membrane. Nevertheless, the function of the enediyene component is well 
established. Upon cellular entry, it encounters a reducing environment in the 
cytoplasm causing its cyclic aromatization leading to biradical formation, which 
causes double strand breaks in the DNA. Like NCS, γ-radiation also produces 
double strand breaks (DSB) but the mechanisms are different. γ-radiation on 
account of high energy causes the molecules inside cells to break up and produce 
ions. The most abundant cellular molecule, water splits up producing hydroxyl 
radicals that cause DNA breaks (Gross, 2007).  
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Figure 1.4 Mechanism of neocarzinostatin action. 
Neocarzinostatin (NCS) is a radiomimetic consisting of two components, a protein part and 
an enediyene part. Upon entry into cell, Enediyene undergoes cyclic aromatization 
producing biradical. The cyclic biradical is considered to induce double strand DNA breaks.  
Figure modified from (Goldberg, 1991). 
 
1.6 DNA damage response and repair  
1.6.1 DNA damage 
DNA is the information storehouse and any damage to it is detrimental to cells. 
Damage to DNA can be physical (e.g. chromosomal breakage), base alterations 
(e.g. deamination), or strand breaks (e.g. single or double). Any physical, chemical 
or biological agent that compromises the integrity of DNA can be classified as a DNA 
damaging agent. Intuitively, the cell has put in a number of stringent measures to 
protect the integrity of DNA; these include recognition of DNA damage, cell cycle 
checkpoints to prevent chromosomal imbalances, mitotic catastrophe, and efficient 
DNA repair machinery. Also, the type of DNA damage induced depends on the 
causative agent for example, radiomimetic like NCS lead to double strand breaks, 
cis-platin causes inter strand cross links, and nucleoside analogs like 5-FU and 
gemcitabine induce replication fork stalls. Apart from these exogenous agents, the 
normal metabolism of a cell produces reactive oxygen species (ROS) which are 
equally potent in damaging the DNA.  
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If the DNA damage is undetected or not repaired, it could lead to cell death or tumor 
formation. Tumor genesis begins with mutations in tumor suppressors like p53 or 
oncogenes like c-myc. Nucleoside analogs as described earlier, target the cancer 
cells by misincorporation into DNA leading to either replication fork stalling or 
mutations.  Therefore, understanding DNA damage is crucial for devising cancer 
therapy.  
1.6.2 Mechanism and signaling in response double strand breaks 
Once the DNA has been damaged, the damage must be recognized and depending 
on the type of DNA damage, appropriate repair machineries must be employed. The 
signaling cascade in response to the DNA damage, starting from recognition till 
repair of the DNA is called DNA damage response (DDR). The proteins carrying out 
the DDR can be classified as,  
(i) Sensors (e.g. MRN complex) 
(ii) Transducers (e.g. ATM and ATR) 
(iii) Mediators (e.g. MDC1, 53BP1)and,  
(iv) Effectors (e.g. Chk1 and Chk2) 
The sensors recognize the damage and facilitate the recruitment of other proteins 
while activating the downstream signals. A common protein complex involved in 
DDR is explained in Figure 1.5. The protein complex, MRN is composed of Mre11, 
Rad50 and NBS1 (Nijmegen breakage syndrome) that detects the DNA double 
strand breaks. The MRN complex then recruits Ataxia telangiectasia mutated (ATM) 
while the RPA recruits Ataxia telangiectasia mutated and Rad 3 related (ATR) 
kinase; ATM and ATR are master regulatory kinases that phosphorylate close to 600 
substrates in the cell (Chapman et al., 2012). In the context of DDR, ATM is involved 
in the DNA double strand break repair while ATR is involved in single strand break 
repair (Figure 1.5).  
1.6.3 Signaling for double strand break repair 
In normal cells, ATM is present as an inactive dimer but upon DNA damage it forms 
active monomers (Bakkenist and Kastan, 2003). Once activated it phosphorylates 
H2AX, a histone H2A variant which constitutes about 10% of the total H2A, however 
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this proportion varies depending on the species and the cell type (Rogakou et al., 
1998). Phosphorylated H2AX (Ser139) is commonly referred to as γ-H2AX and is a 
marker for DNA double strand breaks (Kuo and Yang, 2008).  
The γ-H2AX signal spreads for several thousand bases from the site of the DNA 
damage and facilitates the recruitment of downstream repair proteins. It is 
recognized by proteins with tandem BRCT domains or fork head domains (FHA), like 
MDC1, 53 BP1 and NBS1(Kinner et al., 2008). Mediator of Damage Checkpoint 
protein1 (MDC1) is considered to be among the first proteins to recognize γ-H2AX 
and further recruits MRN complex (Stucki et al., 2005).  
Activation of ATM in response to DNA double strand breaks is explained by a two-
step model, in which the MRN complex tethers the DNA ends to promote ATM 
monomerization followed by activation and autophosphorylation of ATM at 
Ser1981(Dupre et al., 2006). NBS1 has an ATM binding domain and it is speculated 
that interaction with NBS1 may prevent the re-association of ATM monomers to 
inactive dimers and that NBS1 functions as an activating cofactor. 
 
 
Figure 1.5 DNA double strand breaks induced response. 
DNA double strand breaks are recognized by MDC1 which recruits the Mre11-Rad50-Nbs1 
complex. MRN complex activates ATM kinase which in return activates p53 leading to cell 
cycle arrest and apoptosis, Chk2 leading to cell cycle arrest. Figure modified from (Lukas et 
al., 2011) 
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1.7 DNA damage response and apoptosis 
There are many modes of cell death like apoptosis, necrosis, autophagy and 
cornification (Kroemer et al., 2009). Among these apoptosis is the most studied cell 
death type in cancer biology. Apoptosis is defined as a programmed cell death, and 
can be broadly classified as extrinsic and intrinsic apoptosis. In the extrinsic 
pathway, apoptosis is triggered by external stimuli like a ligand that binds to a 
special kind of receptors, called as death receptors. The death receptors belong to 
the tumor necrosis factor superfamily and include cd95 and TRAIL receptor that bind 
to cd95L and TRAIL to induce apoptosis. Binding of ligand to the receptor causes 
trimerization and clustering of the death domain, followed by recruitment of Fas 
Associated protein with Death Domain (FADD). FADD recruits caspase 8 and the 
formation of Death-inducing signaling complex (DISC) leads to self-cleavage of 
caspase 8 and its activation which further activates downstream caspases 
culminating in apoptosis.  
CRC cell lines with both p53 mutant and wild type genotypes exist, for example, 
SW480 harbor a mutant p53 whereas RKO has a functional wild type p53. 
Therefore, it is imperative to understand both p53 dependent and independent 
apoptosis to elucidate the molecular mechanisms behind 5-FU induced apoptosis in 
p53 mutant and wild type CRC cell lines.  
The intrinsic pathway on the other hand does not involve any external stimuli, and is 
activated in response to cells internal signaling processes which get activated 
especially in cases of irreversible DNA damage. Intrinsic apoptosis can be further 
divided into p53 dependent or independent. This is an important distinction as p53 
mutations have been described in more than 50% of the tumors (Vogelstein et al., 
2000). 
DNA damage leads to the activation of the DDR and as described earlier, ATM and 
ATR are the key protein kinases activated in this process. ATM and ATR 
phosphorylate p53 at multiple sites which prevent the interaction of p53 with Mdm2, 
the negative regulator of p53 (Saito et al., 2002), phosphorylation by Chk2 at Ser20 
is also responsible to reduce the interaction with Mdm2 (Ou et al., 2004). The p53 
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protein activates transcription of Bcl2 family of proteins including Bax, Noxa and 
PUMA. Apart from increasing the transcription of pro-apoptotic genes p53 binds to 
the anti-apoptotic genes Bcl-2 and Bcl-XL and prevents their action (Nakanoko et al., 
2013). 
The kinase Chk2 plays a major role in the p53 independent apoptosis. It 
phosphorylates and activates the transcription factor E2F-1 (Stevens et al., 2003). 
E2F-1 has been shown to promote the expression of a variety of apoptotic factors 
and also p53 related protein p73, which can activate pro-apoptotic genes. Apart from 
Chk2, Nur 77 a gene that codes for an orphan receptor is translocated to cytosol in 
response to 5-FU treatment where it is shown to facilitate the release of 
mitochondrial cytochrome c (Calnan et al., 1995). Caspase-2 then promotes 
apoptosis by causing mitochondrial dysfunction and later in the apoptosis relocalizes 
from the nucleus and aids in the translocation of Bax and release of cytochrome c 
and Smac leading to apoptosis (Guo et al., 2007). 
 
 
Figure 1.6 p53 dependent and independent apoptosis. 
Apoptosis induced in response to DNA damage can be executed in both p53 dependent and 
independent manner. Both the pathways converge on mitochondrial release of cytochrome 
c.  Figure modified from (Norbury and Zhivotovsky, 2004).  
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1.8 Cell cycle regulation and cancer  
Cyclins (cyc) and cyclin dependent kinases (Cdk) control the transition from one cell 
cycle phase to next. In humans, Cdk are encoded by 13 loci and cyclins by 25 
though not all of the cyclin-Cdk complexes are involved in cell cycle (Malumbres and 
Barbacid, 2005). There are 10 cyclins belonging to four different families: A, B, D 
and E. In the G1 phase, cycD forms complex and activates Cdk4 and Cdk6 which 
leads to expression of cycE, cycE-Cdk2 complex is crucial for G1/S transition. In the 
S phase, the cycE-Cdk2 complex is active, but during the late S phase the 
expression of cycA2 increases thus, cycE-Cdk2 complex is replaced by cycA2-Cdk2 
complex which facilitate transition into G2. In interphase, cycA activates Cdk1 but 
the nuclear envelope breakdown increases the cycB-Cdk1 complex and this drives 
the cell through mitosis (Figure 1.7).    
Cdk4 overexpression has been reported in melanomas and Cdk6 overexpression in 
breast tumors. cycD2 and D3 are also found to be overexpressed in tumors; cycA 
and E are overexpressed in lung carcinoma while Cdc25B is overexpressed in 
breast tumors. Numerous reports have shown a causal link between cyc and/or Cdk 
overexpression and tumor formation (Guha, 2012). Given this, it is conceivable that 
cyc and Cdk are expected to have anti-tumor activity. Olomuoucine inhibits cycB-
Cdk1, cycA-Cdk2, and cycE-Cdk2 leading to reduced cell proliferation and increased 
apoptosis (Vesely et al., 1994). Recently, Cdk4/6 inhibitor Palbociclib was shown to 
improve the median progression free survival from 7.5 months to 26 months, but this 
drug is still in phase II clinical trials (Kelly et al., 2013).   
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Figure 1.7 Control of cell cycle by cyclin-Cyclin dependent kinase complexes. 
Periodic changes of cyclins regulate activity of Cdk and transition through cell cycle phases. 
Figure modified from (Bardin and Amon, 2001). 
 
1.8.1 Cell cycle checkpoints 
The cyclical passage of cells from a metabolically active state to duplication and 
production of two daughter cells constitutes the cell cycle. During this complex 
process the cell has to take some very critical decisions such as- 
(i) Is there enough energy available to complete the entire process,  
(ii) Is the DNA damaged? 
(iii) Have the chromosomes properly segregated?   
Intuitively, the cell has a complicated but elegant machinery to guard against any 
untoward incident that will have serious effects on either of the daughter cells. This 
machinery operates during cell cycle checkpoints and can be rightly called as 
guardians of the cell.  The checkpoints needed to understand the current study 
include -  
G1/S checkpoint 
The G1/S checkpoint is activated in response to DNA damage and prevents the cell 
from entering the S phase. The key protein involved in the G1/S arrest is p53. 
Phosphorylation by ATM/Chk2 increases its stability, which leads to the transcription 
of genes like p21 that effectuate G1 arrest by inhibiting the cycE-Cdk2 (Coqueret, 
2003). Activation of the DDR leads to increased activity of the kinases Chk1 (only in 
late G1) and Chk2, that phosphorylate Cdc25A (phosphatase required for 
progression into S phase) increasing its degradation by the proteasome (Falck et al., 
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2001). Reduced levels of Cdc25 A inactivate the cycE-cdk2 thereby causing a G1 
arrest.  
Intra S phase checkpoint 
The S phase checkpoint is activated in response to damaged DNA. The cell must 
first repair the DNA and complete synthesis before moving into G2 and M phases, as 
once it leaves the S phase, DNA replication and synthesis are not possible. Here, 
Cdk2 inhibition by Chk1- and Chk2- mediated phosphorylation of Cdc25, prevents 
the DNA polymerase from assembling on to replication sites and thus prevents the 
firing of new origins of replication leading to S phase arrest. 
G2/M checkpoint 
The G2/M checkpoint depends on the ATM/ATR mediated phosphorylation and 
inhibition of cycB-Cdk1, that is required for the mitosis. Activation of Cdk1 requires 
Cdc25, however ATM/ATR mediated phosphorylation of Cdc25 prevent the 
activation of Cdk1, thereby preventing entry into M phase.   
 
1.9 DNA double strand break repair processes   
1.9.1 H2AX and Homologous Recombination Repair 
γ-H2AX has been shown to have only modulating effect in homologous 
recombination repair (HRR). H2AX deletion mice show increased genomic instability 
but are not embryonic lethal, however mice lacking components of HRR are 
embryonic lethal indicating that γ-H2AX is not necessary for HRR but can function to 
improve the efficiency of the HRR (Yin et al., 2012). It is known that MRN complex 
can recognize the DNA double strand breaks and perform limited end resection 
needed for HRR (Dong et al., 2012). However, normally Exo1 performs the end 
resection and is recruited to the sites of DNA damage by MRN complex. Once end 
resection is completed the ssDNA is covered by RPA that protects the ssDNA from 
degradation and prevents secondary structure formation.  
The recruitment of Rad51 a key regulator of HRR depends on many factors like 
BRCA1, Ring finger protein 8 (RNF8), and p400 (Nakada et al., 2012). It is not yet 
clear which factor contributes to the recruitment and to what extent although RNF8 
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may be a good guess as it is also involved in the DDR. Another important aspect is 
the replacement of RPA by Rad51 to facilitate HRR which is aided by Rad52 and 
Rad55-57 complex (Liu et al., 2002). Rad52 binds to Rad51 and is primarily required 
for the formation of Rad51 filaments on the DNA and its interaction with RPA allows 
it to detect the ssDNA. Rad52 is phosphorylated at Tyr104 by c-Abl kinase 
increasing its affinity to ssDNA. C-Abl is activated by ATM or DNA-PK thus linking 
the activation of Rad52 to DDR (Honda et al., 2014). The Rad55-57 heterodimer 
also interacts with Rad51 and facilitates its loading onto RPA coated ssDNA. Rad51 
filament is shown to be more resistant to Srs2 anti-recombinase in the presence of 
Rad55-57 heterodimer. It has been shown that Rad55 is phosphorylated at Ser2, 8 
and 14 by Rad53 kinase in S.cerevisiae and that these phosphorylation events are 
necessary for efficient HRR. The human homolog of the Rad53 is Chk2, which is 
phosphorylated by ATM in response to DSB therefore these observations can be 
extrapolated to mammalian cells albeit with caution.  
RPA is a heterotrimeric protein composed of 3 subunits, RPA1 (70 kDa), RPA2 (34 
kDa) and RPA3 (14 kDa). RPA is phosphorylated at multiple sites and subunits in 
response to DNA damage. Cdc2 cyclin dependent kinase phosphorylates RPA2 at 
Ser23 and Ser29 facilitating the recruitment and binding to ssDNA, while PIKK 
phosphorylates RPA2 at Ser4, 8, 11, 12, 13, 33 and Thr21 (Figure 1-8). This 
hyperphosphorylation is speculated to regulate the functioning of the RPA molecule 
but the exact role of each phosphorylation event is not entirely known (Summers et 
al., 2011). 
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Figure 1.8 Phosphorylation sites in Rad51 and RPA2. 
Rad51 and RPA2 are phosphorylated at multiple sites which regulate their function, 
localization and activation. All known phosphorylation sites are indicated in blue and the 
domain structures are indicated in gradient of black. Images were obtained using PTMcode 
2. AAA- ATPases Associated with diverse cellular Activities; RPA_C – oligonucleotide 
binding fold.  
 
1.9.2 Homologous recombination repair 
Homologous recombination repair (HRR) is considered to be an error free DNA 
repair process that repairs the DNA double strand breaks using a sister chromatid or 
homologous stretch of DNA. The use of homologous DNA strand makes this process 
error free though loss of heterozygosity may occur due to the same reason.  
For description, HRR is usually divided into 3 phases; (a) Presynaptic; (b) Synaptic; 
(c) Post synaptic. The presynaptic phase involves, (a) end resection, (b) binding of 
RPA and (c) loading of Rad51 filaments on to the DNA. End resection is a complex 
process that involves Exo1 (protein with exonuclease activity), Dna2, CtIP and BLM 
helicase. As described above the mediators facilitate the loading of Rad51 while 
removing the RPA from the sites of DNA damage. Rad51 has five paralogs in 
mammals Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3 (Masson et al., 2001). 
All the paralogs of Rad51 have the ability to form filaments on the DNA but they do 
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not have the recombinase activity possessed by Rad51. The presynaptic phase 
ends with the loading of Rad51 on to the DNA (Figure 1-9).  
 
 
Figure 1.9 Mechanism of homologous recombination repair. 
MRN complex recognizes DNA double strand breaks followed by end resection producing 
ssDNA bound by RPA. Rad51 is recruited at the sites of bound RPA followed by strand 
invasion and DNA synthesis. Figure modified from (Heyer et al., 2010) 
 
During synapsis Rad51 starts the homology search; this process is aided by the 
mediator protein Rad54 (Mazin et al., 2010). Once the homologous region is found 
the 3’ overhang is used to initiate DNA synthesis. The DNA synthesis in the D-loop 
(Figure 1.9) is completed by DNA polymerase η, but in its absence other 
polymerases have been speculated to take over this function (Sebesta et al., 2013). 
After the completion of synthesis, newly synthesized DNA strand is released by the 
sliding of the Holliday Junction (HJ) whose migration is aided by Rad54, BLM and 
other proteins, but the extent of their role is still unclear (Bugreev et al., 2006). 
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Finally the 3’ end of the released strand is ligated to give a repaired DNA. The 
processing of the released DNA depends on the extent of DNA synthesis, for 
example if the newly synthesized makes flap, i.e. an overhang, then specific 
endonucleases are employed to remove the excess nucleotides before filling the 
gaps and ligation (Kikuchi et al., 2005). Final DNA synthesis is performed by DNA 
polymerase δ or ε (Maloisel et al., 2008). The end products obtained after 
homologous recombination depend on the resolution of the HJ giving either a 
crossover or a non-crossover product. As detailed in Figure 1.9, there are many 
more proteins and sub pathways that ultimately decide the fate of the products. 
Discussing all the sub pathways and the functions of proteins in details is beyond the 
scope of the present text.  
1.9.3 Non-homologous end joining 
Non-homologous end joining (NHEJ) is a DNA double strand break repair process 
that does not use a homologous template for the repair and consequently, it is more 
prone to errors. NHEJ bluntly joins the two ends and ligates them without the 
concern for the loss of information on the DNA during the process. Though, in most 
cases the information may not be lost but because of the nature of repair the 
chances are high. NHEJ is the preferred pathway for repairing the DNA double 
strand breaks in the G1 phase when the sister chromatids are not present (Sebesta 
et al., 2013). The advantage of this process is that it is quick and requires very little 
energy to complete the repair.  
In its simplest form, NHEJ involves the binding of Ku70/80 heterodimer to the double 
strand breaks, followed by recruitment and activation of DNA-PKCS (Figure 1.10). 
This complex brings the two ends close together and the DNA ligase IV ligates the 
broken ends to complete the repair (Lieber, 2010). In more complex cases where the 
3’ end may contain a phosphate group or the sugar backbones may be damaged a 
more elaborate system is employed. For example, WRN protein using its 
exonuclease activity can remove damaged nucleotides; Artemis nuclease can cleave 
hairpin structures (Davis and Chen, 2013). 
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Figure 1.10 Mechanism of non-homologous end joining. 
Ku70/80 heterodimer recognizes the DNA double strand breaks followed by recruitment of 
DNA-PKCS and this complex holds the DNA ends together DNA ligase IV ligates the DNA 
with help from XRCC4 and XLF. Figure modified from (Osolodkin et al., 2013). 
 
1.9.4 Interplay and regulation of repair pathways 
Both HRR and NHEJ perform the double strand break repair in mammalian cells and 
this adds an additional layer of complexity in cells to regulate the two pathways. 
Ideally, a cell would like to employ the error free HRR to maintain the integrity of the 
genome but, as described earlier this is not feasible in all cases. 
 One of the key regulators in this balancing act is CtIP, the human homolog of yeast 
Sae2 (Penkner et al., 2007). CtIP is phosphorylated at Ser327 and Thr847 in the S 
phase by Cdk2, the latter phosphorylation is required for ssDNA generation and RPA 
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phosphorylation both of which are needed for HRR. Phosphorylation at Ser327 is 
required for the interaction with BRCA1 and this phosphorylation of CtIP is restricted 
to the S/G2 phase promoting the HRR (Yu and Chen, 2004). Furthermore, BRCA2 a 
protein that plays a critical role in the Rad51 filament formation is dephosphorylated 
in the S phase paving way for its interaction with Rad51, which also promotes HRR 
(Esashi et al., 2005). BRCA2 is phosphorylated at Ser3291 by cycA-Cdk2 in the M 
phase thus preventing its interaction with Rad51 and hence HRR.  
Apart from the cell cycle regulators of HRR, BLM sumoylation on Lys317 and Lys331 
increases the end resection thus favoring the HRR. Apart from the cell cycle 
regulations, checkpoint kinases Chk1 and Chk2 also influence the fate of HRR. Chk1 
is majorly expressed in S and G2 phases of a cell cycle and is known to 
phosphorylate Rad51 at Thr309 facilitating latter’s recruitment on to the chromatin, 
and as described earlier, Chk2 kinase phosphorylates the mediator Rad55 that 
facilitates loading of the Rad51 on the RPA coated DNA (Feijoo et al., 2001).  
NHEJ is regulated by the DNA-PKCS autophosphorylation and ATM. DNA-PKCS is 
phosphorylated at a cluster of six residues that includes Thr2609, Ser2056 and 
Thr3950. It has been reported that in S phase, phosphorylation of the clusters 
Thr2609 and Ser2056 is reduced, down regulating NHEJ (Summers et al., 2011). 
The cell may use all of the above mentioned mechanisms to ensure that HRR stays 
active in S and G2 phases of the cell cycle while the NHEJ remains active in G1 
phase (Figure 1-11). 
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Figure 1.11 Cell cycle dependence of HRR and NHEJ. 
In the G1 phase, CtIP is present in its inactive dephosphorylated form while BRCA2 is 
phosphorylated preventing its interaction with Rad51 and this setup favors the NHEJ. In the 
S phase, CtIP is phosphorylated by CDK2 making it active and BRCA2 is dephosphorylated 
allowing it to interact with Rad51, this setup favors the HRR. In the M phase the CtIP is 
dephosphorylated and BRCA2 is phosphorylated favoring NHE over HRR. Figure modified 
from (Ciccia and Elledge, 2010). 
 
1.9.5 DNA double strand break repair and cancer development  
Homologous recombination because of its function, as described earlier, is integral 
to guard the genome against DNA double strand breaks. Mutations in HRR lead to 
gene rearrangements that can pave way for cancer development and are described 
in many cancers. Mutations in BRCA1 and BRCA 2 are associated with breast 
cancer predisposition, while mutations in Rad54 and CtIP are observed in non-
Hodgkin’s lymphoma. Rad51 B has been reported to be mutated in uterine 
leiomyoma (Jasin, 2002; Schoenmakers et al., 1999; Wong et al., 1998). Rad51 
protein expression is reduced in breast cancer but so far it has not been directly 
implicated in the development of breast cancers.  
There are contrasting reports on the involvement of NHEJ in cancer development, 
with some groups claiming Ku70 mutation increases the incidence of lymphomas 
while some argue otherwise (Burma et al., 2006). Till date no particular mutation in 
NHEJ has been associated with tumor development in humans; however, loss of 
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artemis and DNA ligase IV have been associated with immunodeficiency (Simsek et 
al., 2011).  
  
1.10 Mismatch repair system 
As the name suggests, Mismatch repair (MMR) machinery rectifies the mismatches 
in the DNA. Apart from the base:base mismatches MMR also tackles the insertion-
deletion loops (IDL). Base:base mismatches arise due to an occasional mistake in 
the proofreading by the DNA polymerase.  
1.10.1 Mechanism  
In E.coli, the mismatches are first recognized by the MutS homodimer which then 
recruits the MutL homodimer to the DNA (Jiricny, 2006). Subsequently, the formation 
of MutS, MutL and ATP complex activates MutH whose endonuclease activity is 
stimulated by the presence of aforementioned complex (Figure 1-12). The activated 
MutH nicks the newly synthesized strand, and UvrD, a helicase unwinds the nicked 
strand followed by exonucleolytic degradation. DNA polymerase III synthesizes new 
DNA strand followed by DNA ligase that seals the nick.      
The mammalian system is more complex with many homologs and regulatory 
signaling (Pena-Diaz and Jiricny, 2012). Mammals have five homologs of MutS of 
which three participate in MMR namely, MSH2, MSH3 and MSH6. These proteins for 
heterodimers and the most abundant of them is MSH2-MSH6. The MSH2-MSH6 
heterodimer is called as MutSα while the other major heterodimer MSH2-MSH3 is 
known as MutSβ. In the mammals it is these two complexes that recognize the 
mismatches or the IDL and then recruit the MutLα (a heterodimer of MLH1 and 
PMS2).  Replication factor C (RFC) is required for loading the PCNA but when the 
sliding clamp (MutSα) reaches the nicked end RFC is replaced with EXO1. EXO1 
uses its exonuclease activity to degrade the DNA strand and Polδ synthesizes the 
new DNA strand.  
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1.10.2 Interplay in HRR 
MMR plays a critical role in HRR, by preventing DNA synthesis during strand 
invasion in regions with mismatches. This becomes especially important when the 
HRR is occurring between two divergent sequences. MMR can either reject the 
invading strand thus preventing HR or repair the mismatch before HRR can proceed 
(Pena-Diaz et al., 2012). In case of repair, the invading strand is repaired so as to 
attain proper base pairing with the template strand and this leads to change in the 
sequence of the repaired DNA strand. It has been recently shown that hMSH2-
hMSH6 recognizes the mismatches in the D-loop and can reject the invading strand 
in case of divergent sequences (Honda et al., 2014).              
1.10.3 MMR and Colorectal cancers 
CRC cell lines can be broadly classified as Chromosomal instable (CIN) or 
Microsatellite instable (MSI) based on their MMR status. The cells with a proficient 
MMR status are CIN while the cells with deficient MMR are MSI. CIN contributes 70-
85% (Worthley and Leggett, 2010) for the generation of CRC making it therefore a 
more interesting study. The cell lines SW480, SW620 used in this study fall under 
the category of CIN while the HCT 116 is MSI cell line. 
 
Table 1.2 CRC cell lines used in the study and their p53 and MSI/CIN status MMR and 
DDR 
Cell line Type p53 status CIN/MSI 
SW480 Colorectal Mutant CIN 
SW620 Colorectal Mutant CIN 
SW837 Colorectal Mutant CIN 
HCT116 Colorectal Wild type MSI 
HCT116 p53-/- Colorectal Null MSI 
HT-29 Colorectal Mutant MSS 
HCT15 Colorectal Mutant MSI 
RKO Colorectal Wild type MSI 
LoVo Colorectal Wild type MSI 
Colo320 Colorectal Mutant MSS 
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It is conceivable, that in the process of repairing the mismatches MMR may 
encounter replication fork stalls, as in the case of gemcitabine. The fork stalls lead to 
ssDNA which is a substrate for RPA which then activates the ATR pathway. Chk1, a 
substrate of ATR, upon activation can cause cell cycle arrest. Furthermore, it has 
been shown that MSH2 forms complexes with Chk2, Chk1 and ATR (Adamson et 
al., 2005). 
 
Figure 1.12 Mechanism of mismatch repair. 
Mismatch repair system recognizes mismatches in DNA and then removes the lesions in the 
DNA followed by fresh DNA synthesis. MMR is a primary repair machinery that recognizes 
mismatches induced by 5-FU. Figure modified from (Pena-Diaz and Jiricny, 2012) 
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1.11 Scope of the thesis  
The major concern in the clinical treatment of CRC is the poor response rates of the 
current regimens in advanced colorectal tumors. Diagnosis of the tumors during 
stage I increase the response rates of 5-FU based therapies to over 90% whereas, 
the response rates fall to below 40% in the patients diagnosed in stage III and IV. 
Therefore, the challenge is to improve the response rates of the patients diagnosed 
in the late stages of the tumor and to find predictive biomarkers for tumors. As 
discussed earlier, HNPCC has been successfully used to predict the onset of CRC; 
however, a very small fraction of CRC’s have germline mutations in HNPCC and 
most of the cases are due to spontaneous mutations leading to tumor formation. In 
this work, we aim to investigate the molecular mechanism behind the action of 
neoadjuvant therapy in context of DDR. We focus on 5-FU and NCS based therapy, 
and use SW480 cells, a CRC cell line as our main model. Apart from being CIN 
which enlarges the scope of our findings to most CRC types, SW480 cells are 
morphologically pliable and resistant to 5-FU. This makes them an apt choice for 
unraveling DDR in CRC. We also attempt to elucidate the molecular mechanism 5-
FU induced radiosensitization and the role of TS in 5-FU based regimens. Next, we 
compare the mechanisms and efficacy of gemcitabine in context of CRC. Our hope 
is that our studies will serve as a framework for devising better 5-FU based CRC 
therapies that exhibit improved response rates, especially in patients that develop 
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2 Materials 
2.1 Human cell culture 
Table 2.1 Human cell lines 
Cell line Origin 
SW480 Colorectal cancer cell line; mutant p53;chromosomal instable 
SW620 Colorectal cancer cell line; mutant p53;chromosomal instable 
HeLa Cervical cancer cell line; no p53 expression 
HCT116 
p53+/+ 
human colon carcinoma cell line 
HCT116 p53-/- p53-deficient human colon carcinoma cell line (Bunz, 1998) 
 
Table 2.2 Media and reagents for eukaryotic cell culture 
Reagent Company 
Ciprofloxacin Bayer 
Dulbecco’s Modified Eagle Medium (DMEM), powder Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
McCoy’s Medium Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM, powder 10.0 g/l 
NaHCO3 3.7 g/l 
HEPES 5.96 g/l 
dissolved in H2O 
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Dulbecco’s Modified Eagle’s Medium (DMEM) with 
supplements 
DMEM  
FCS 10 % 
Penicillin/Streptomycin 50 U/ml 
L-Glutamine 200 µM 
Ciprofloxacin  10 µg/ml 
dissolved in H2O 
  
McCoy’s Medium with supplements 
McCoy’s medium  
FCS 10 % 
Penicillin/Streptomycin 50 U/ml 
L-Glutamine 200 µM 
dissolved in H2O 
Chemotherapeutics and pharmacological inhibitors 
 
Table 2.3 Chemotherapeutics 
Name Company 
5-Fluorouracil Sigma-Aldrich, F6627 
Neocarzinostatin (NCS) Sigma-Aldrich, #N9162 
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Table 2.4 Inhibitors 
Name Target Company 




MG132 Proteasome Calbiochem, #474791 
Z-VAD Caspases Sigma, #V116-2mg 
 
2.2 Consumables 
Table 2.5 Consumables 
Product Company 
96-well plates for flow cytometry Becton Dickinson 
96-well plates for microscopy, clear bottom Becton Dickinson 
96-well plates for microscopy, clear bottom Corning 
96-well plates for qPCR 4titude 
96-well plates OptiplateTM 96 for luciferase 
assay 
Perkin Elmer 
Bacteria culture dishes Sarstedt 
Bacteria culture vials (14 cm) Becton Dickinson 
Cell culture dishes (10 cm, 15 cm) Greiner 
Cell culture plates (6-well, 12-well) Greiner 
Cell scraper (16 cm, 25 cm) Sarstedt 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Electroporation cuvette Gene Pulser Bio-Rad Laboratories 
Filter tips (10 µl) Starlab 
Filter tips (20 µl, 200 µl, 1,000 µl) Sarstedt 
Parafilm Brand 
Pipet tips (10 µl, 20-200 µl, 1,000 µl) Greiner 
Pipet tips for screen (50 µl, 200 µl) Beckman Coulter 
Protran nitrocellulose transfer membrane Whatman 
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Reaction tube (0.2 ml) Sarstedt 
Reaction tube (0.5 ml, 1.5 ml, 2.0 ml) Eppendorf 
Reaction tube (15 ml, 50 ml) Greiner 
Reservoir Beckman Coulter 
Reservoir (divided by length) Beckman Coulter 
Safe-lock reaction tube (1.5 ml) Eppendorf 
Sealing foil for 96-well plate Becton Dickinson 
Sterile filter Millipore, Merck 
Syringe Henke-Sass 
Syringe cannula (different sizes) B.Braun 
Transparent sealing foil for 96-well plate 4titude 
Whatman paper Whatman 
 
2.3 Technical devices 
Table 2.6 Technical devices  
Device Company 
Automated Cell Counter Countess® Invitrogen, Life Technologies 
Biomek 2000 Laboratory Automation 
Workstation 
Beckman Coulter 
Blotting chamber  Biozym 
Cell counting chamber Neubauer 
improved 
Brand 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific 
Chemiluminescence imager Chemocam 
HR 16 3200 
Intas Science Imaging Instruments 
Cytometer Celigo Cyntellect 
DNA gel chamber Biotech Service Blu 
Electrophoresis system for SDS-PAGE Amersham Biosciences, GE Healthcare 
 Materials 32 
Electroporator GenePulser II Bio-Rad Laboratories 
  
FACS machine EasyCyte plus Guava Technologies, Millipore 
Foil swelding machine Vacupack plus Krups 
Freezer -20 °C Liebherr 
Freezer -80 °C Heraeus, Thermo Scientific 
Heating Block Grant Instruments 
Heating Block HLC HLC Biotech 
Ice-machine B100 Ziegra 
Incubator for bacteria Memmert 
Incubator for bacteria Minitron Infors HT 
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton 
Luminometer DLReady™ Centro LB 960 Bertold Technologies 
Magnetic stirrer MR3001 Heidolph 
Microscope Axovert 40C Zeiss 
Microscope Axioscope 2 Plus  
Microscope, automated Pathway 855 Becton Dickinson 
Microwave  Cinex 
Mini Centrifuge MCF-2360 LMS 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Primus 25 advanced Peqlab 
pH-meter WTW-720 WTW 
Pipet Multipette Eppendorf 
Pipet, electric Portable-XP Drummond 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μL; 0.5-10μL; 10-100μL; 100-
1000μL) 
Eppendorf 
Pipette, multichannel Research Plus Eppendorf 
Power supply unit Powerpack P25T Biometra 
Refrigerator 4°C Liebherr 
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Roller RM5 V-30 CAT 
Rotating wheel Test-tube rotator 34528 Snijders 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon 
Sequencer, automated ABI 3100 Applied Biosystems, Life Technologies 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor Diagenode 
Spectrophotometer NanoDrop ND-1000 PeqLab 
Thermomixer comfort Eppendorf 
UV-transilluminator Intas UV system Gel 
Jet Imager 
Intas Science Imaging Instruments 
Vacuum pump IBS Integra Biosciences 
Vortex genie 2 Scientific Industries 
Water bath TW 20 Julabo Labortechnik 
 
2.4 Chemicals and reagents 
Table 2.7 Chemicals and reagents 
Substance Company 
Acetic acid Roth 
Acrylamide/bisacrylamide (A/BA) Roth 
Adenosin triphosphate (ATP) Fermentas, Thermo Scientific 
Agar Sigma-Aldrich 
Agarose Roth 
Albumin Fraction V (Bovine Serum Albumine, 
BSA) 
Roth 
Ammonium persulfate (APS) Roth 
Ammonium sulfate ((NH4)2SO4) Roth 
Ampicillin AppliChem 
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Aprotinin AppliChem 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) Roth 
Chloroform Roth 




Coenzyme A sodium salt hydrate Sigmal-Aldrich 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Sigma-Aldrich 
D-Luciferin ICN 
DNA ladder GeneRuler Fermentas, Thermo Scientific 
Deoxyribonucleotide triphosphates (dNTPs) Bio-Budget 
Deoxyribonucleotide triphosphates (dNTPs) in 
single tubes 
Primetech 
Dipotassium phosphate (K2HPO4) Roth 
Dithiothreitol (DTT) Roth 
DNA stain clear G (39804) Serva 
Ethanol 99.8% Roth 
Ethanol 99.9% p.a. (EtOH) Merck 
Ethylene diamine tetraacetatic acid (EDTA) Roth 
Ethylene glycol tetraacetic acid (EGTA) Roth 
Fetal calf serum HyClone Thermo Scientific 
Formaldehyde, 37% solution Roth 
Glycerol Roth 
Glycine Roth 
Glycogen blue Ambion, Life Technologies 
Glycylglycine AppliChem 
Guava ICF Cleaning Solution Millipore, Merck 
HEPES Roth 
Hi-Di Formamide Applied Biosystems, Life 
Technologies 
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Hoechst 33342 Invitrogen, Life Technologies 
Hydrogen chloride (HCl) Roth 
Isoamyl alcohol Roth 
Isopropanol Th. Geyer 
Kanamycin sulfate AppliChem 
Leupeptin Hemisulfat AppliChem 
Lipofectamine™ 2000 (LF2000) Invitrogen, Life Technologies 
Magnesium chloride (MgCl2) for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate (MgCl2 x 
6H2O) 
Roth 
Magnesium sulfate (MgSO4) AppliChem 
Methanol >99% (MetOH) Roth 
N-ethylmaleimide (04260) Fluka  
Nonidet P-40 substitute (NP-40) Sigma Aldrich 
Nuclease free water Ambion, Life Technologies 
Page Ruler™ Prestained Protein Ladder Fermentas, Thermo Scientific 
Passive Lysis Buffer (E1941) Promega 
Pefabloc SC protease inhibitor Roth 
Pepstatin A AppliChem 
Ponceau S Roth 
Potassium chloride (KCl) Roth 
Potassium hydrogenphosphate (KH2PO4) Roth 
Powdered milk Roth 
Propidium iodide (PI) Sigma-Aldrich 
Protein A Sepharose (PAS) Invitrogen, Life Technologies 
Protein G Sepharose (PGS) GE Healthcare 
RNase inhibitor Fermentas, Thermo Scientific 
Roti-Phenol Roth 
Rotiphorese Gel 30 Roth 
Sodium acetate (NaAc) Roth 
Sodium azide (NaN3) AppliChem 
Sodium bicarbonate (NaHCO3) Roth 
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Sodium chloride (NaCl) Roth 
Sodium deoxycholate AppliChem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium hydrogenphosphate heptahydrate 
(Na2HPO4 x 7H2O) 
Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sucrose Sigma-Aldrich 
SYBR Green Invitrogen, Life Technologies 
Tetracycline Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
Thymidine Sigma-Aldrich 
Trasylol Bayer, Leverkusen 
Trehalose Sigma-Aldrich 
TRIS Tris(hydroxymethyl)aminomethane 
Trisamine (Tris) Roth 
Triton X-100 Applichem 
Trizol Invitrogen, Life Technologies 
Tween 20 Applichem 
Yeast extract Sigma-Aldrich 
β-Mercaptoethanol Roth 
 
2.5 Buffers and Solutions 
RIPA lysis buffer, pH 7.5 




SDS 0.1 % 
NaCl 150 mM 
EDTA 10 mM 
Tris-HCl, pH 7.5 20 mM 
SDS running buffer 
Tris 25.0 mM 
Glycin 86.1 mM 
SDS 3.5 mM 
dissolved in H2O 
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Trasylol 50,000 KIU 
dissolved in H2O 
 
Cell lysis buffer 
Urea 2 M 
RIPA lysis buffer 100% 
protease inhibitors:  
Pefabloc 10 µM 
Pepstatin A 1 µg/ml 
Leupeptin/Aprotinin 1 µg/ml 
 
Laemmli buffer, 6x 
Tris pH 6.8 0.35 M 
Glycerin 30.00 % 
SDS 10.00 % 
Dithiotreitol 9.30 % 
Bromophenol blue 0.02 % 
dissolved in H2O 
 
Ponceau S solution  
Ponceau S 0.5 % 
Acetic acid 1.0 % 






Tris buffered saline + Tween 20 
(TBST), pH 7.6 
Tris 50 mM 
NaCl 150 mM 
Tween 20 0.1 % 
dissolved in H2O 
 
Western blot blocking solution 
Milk powder 5 % 
dissolved in TBST 
 
Western blot blocking solution for 
phospho-antibodies 
BSA 5 % 
dissolved in TBST 
 
10x Western Salt buffer, pH 8.3 
Tris 250 mM 
Glycin 1,92 M 
SDS 0.02 % 
dissolved in H2O 
 
Western blot transfer buffer, pH 8.3 
10x Western Salt 
buffer 
10 % 
Methanol 20 % 
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10x Phosphate buffered saline 
(PBS), pH 7.5 
NaCl 240.0 mM 
KCl 2.7 mM 
Na2HPO4 x 7H2O 8.1 mM 
KH2PO4 1.5 mM 
dissolved in H2O 
 
 
DNA gel loading buffer, 6x 
Sucrose 40 % 
Glycerin 10 % 
Bromophenol blue 0.25 % 
dissolved in H2O 
 
TAE buffer 
Tris  40 mM 
Acetic acid 20 mM 
EDTA 2 mM 
dissolved in H2O 
 
IF blocking solution 
FCS 5 % 
Triton X-100 0.1 % 
dissolved in PBS 
dissolved in H2O 
 
qPCR reaction buffer, 10x 
Tris-HCl, pH 8,8 750 mM 
(NH4)2SO4 200 mM 
Tween 20 0.1% 
dissolved in H2O 
qPCR reaction mix 
10x qPCR reaction 
buffer 
10 % 
SYBR Green 1:80,000 
MgCl2 3 mM 
Trehalose in 10 mM 
Tris, pH 8,5 
300 mM 
dNTPs 0.2 mM 
Triton X-100 0.25 % 
Taq polymerase 20 U/ml 
dissolved in H2O 
(shock-frozen in liquid nitrogen and  
kept at -20 °C) 
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2.6 Enzymes and buffers 
Table 2.8 Enzymes and buffers 
Reagent Company 
Buffer for HindIII Fermentas, Thermo Scientific 
Buffer for M-MuLV RT, 10x New England Biolabs (NEB) 
Buffer for Taq (KCl+, -MgCl2), 10x Fermentas, Thermo Scientific 
Calf Intestine Alkaline Phosphatase  Fermentas, Thermo Scientific 
Cloned Pfu reaction buffer, 10x Stratagene 
KpnI Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) New England Biolabs (NEB) 
Pfu Turbo DNA polymerase (2.5 U/µl) Stratagene 
RNase A (1 mg/ml) Qiagen, Venlo, Netherlands 
T4 ligase (200 U/µl) Fermentas, Thermo Scientific 
T4 ligase buffer Fermentas, Thermo Scientific 
Taq DNA polymerase (Taq) Fermentas, Thermo Scientific 
Taq DNA polymerase (Taq) for qPCR Primetech 
XbaI Fermentas, Thermo Scientific 
 
2.7 Kits 
Table 2.9 Kits 
Name Company 
Guava Check Kit Millipore, Merck 
Immobilon Western HRP Substrate Peroxide 
Solution  
Millipore, Merck 
Invisorb Spin Plasmid Mini Kit Two Invitec, Stratec 
Pierce® BCA Protein Assay Kit Thermo Scientific 
PureYield™ Plasmid Midiprep System Promega 
QIAquick® PCR Purification Kit (250) Qiagen 
SuperSignal West Femto Maximum Sensitivity  Thermo Scientific 
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2.8 Oligonucleotides 
Table 2.10 Small interfering RNAs from Ambion/Life Technologies 
 
Target Sequence siRNA ID 



































RRM2#2 sense: 5-CCAUUUGACUUUAUGGAGAtt-3’ S12361 










Table 2.11 Primers  
Name Sequence Application 
CMV promoter 
forward 
5’-CGC AAA TGG GCG GTA GGC GTG-3’ sequencing 
of plasmids 
anchored oligo-dT 5‘-dT23VN-3‘ RT-PCR 
random nonamer 5’-NNNNNNNNN-3’ RT-PCR 
GAPDH forward 5’-TGA AGG TCG GAG TCA ACG GAT TTG 
GT-3’ 
qPCR 
GAPDH reverse 5’-GCA GAG ATG ATG ACC CTT TTG GCT 
C-3’ 
Chk1 forward  5‘-TGG CGG GAA AAG CGC TGCA T-3‘ 
 
qPCR 





Table 2.12 Plasmids 
Name Description 
pcDNA3-GFP expression vector for green fluorescent protein (GFP) 
DRGFP Plasmid for reporter assay for HRR 
NHEJ plasmid Plasmid for reporter assay for NHEJ 
DsRed Invitrogen 
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pCBAI-SceI Expression vector for I-SceI restriction endonuclease 
 
2.10  Antibodies  
Table 2.13 Primary antibodies for Western blot  
Antibody Source  Company  Cat. No. Application Dilution 
β-Actin mouse Abcam ab6276-100 WB 50,000x 
Caspase 3 rabbit  Cell Signaling 9662 WB 1000x  
Chk1 (2G1D5) mouse Cell Signaling 2360 WB 1000x  
Chk2 mouse Calbiochem CC44 WB 300x 
cleaved Caspase 3 rabbit  Cell Signaling 9664 WB 800x  
p53 (DO1) mouse Santa Cruz sc-126 WB 1000x  
PARP  mouse  Calbiochem  AM30 WB 1000x  
phospho-Chk1 
(Ser317) 
rabbit Cell Signaling 2344 WB 1000x 
phospho-Chk2 (Thr68) rabbit Cell Signaling 2661 WB 1000x 
phospho-H2AX 
(Ser319) 
mouse  Millipore  05-636 WB 2000x  
Rad51 rabbit Santa Cruz Sc-8349 WB 1000x 
Rad51 mouse Abcam ab213 WB 1000x 
RPA1 Mouse Calbiochem #NA13 WB 1000X 
RPA2 Mouse Calbiochem  #NA18 WB 1000x 
Ku70 Mouse Santa Cruz Sc5309 WB 1000x 
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All primary antibodies were diluted in Western blot blocking solution with 5 % milk 
powder. Antibodies against phospho-Chk1 and phospho-Chk2 were diluted in 
Western blot blocking solution with 5 % BSA. 
Table 2.14 Primary antibodies for immunofluorescence 
Antibody Source  Company  Cat. No. Dilution  
53BP1 rabbit Santa Cruz sc-22760 300x 
H2AX pS139 mouse  Millipore  05-636  1500x 
H2AXpS139 Rabbit Millipore 07-164 1000x 
RPA1 Mouse Calbiochem #NA13 500x  
RPA2 Mouse Calbiochem  #NA18 500x  
Rad51 rabbit Santa Cruz Sc-8349 100x  
Rad51 mouse Abcam ab213 100x  
All primary antibodies were diluted in IF blocking solution with 5 % FCS.  
 
Table 2.15 Secondary antibodies for Western blot 
Antibody Company Cat. No. Dilution 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti-mouse 
IgG (H+L)  
Jackson Immunoresearch 711-036-152  10,000x 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti-rabbit 
IgG (H+L)  
Jackson, Immunoresearch  715-036-150  10,000x 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti-goat IgG 
(H+L)  
Jackson, Immunoresearch  705-036-147 10,000x 
All secondary antibodies were diluted in Western blot blocking solution with 5 % milk 
powder. 
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Table 2.16 Secondary antibodies for immunofluorescence 
 
Antibody Company Cat. No. Dilution 









A-11034  500x 




A-11003  500x 





Click-iT Alexa Fluor 488 HCS Invitrogen, Life 
Technologies 
C10350 500x 
All secondary antibodies were diluted in IF blocking solution with 5 % FCS. 
2.11 Bacteria 
Table 2.17 Bacteria strains 
Strain Description Company 
DH10B  chemically competent E. coli self-made 
Table 2.18 Bacteria culture media 
2YT medium 
Tryptone 1.6% 
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2.12 Software and databases 
Table 2.19 Software 
Name Company 
Adobe Photoshop CS5 Adobe Systems, San Jose, CA, United States 
AttoVision (BD Pathway) Becton Dickinson 
BioEdit v7.0.5  
 
Tom Hall, Ibis Biosciences, Carlsbad, CA, 
United States 
Celigo Software Cyntellect 




FociCounter Open source 
Guava Express Software  Millipore, Merck 
Intas ChemoStar Imager Intas Science Imaging Instruments 
ModFit LT Verity Software House, Topsham, ME, United 
States 
NanoDrop Software Peqlab 
UV imager software Intas Science Imaging Instruments 
MS word Microsoft 
Inkscape Open source GNU 
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3 Methods 
3.1 Cell biology 
3.1.1 Thawing cell lines 
Human tumor cell lines preserved in liquid nitrogen for long term storage were 
thawed at 37oC and immediately transferred to a pre warmed 10 ml cell culture 
medium in a falcon tube and centrifuged at 0.8 x g for 5 m. Supernatant was 
removed in a sterile cell culture hood and the pellet was re-suspended in fresh cell 
culture media. The cells were cultured in a 10 cm2 petri dish and incubated at 
37oC/5% CO2 till they reached a confluency of 70-80%.  
3.1.2 Passaging human tumor cell lines 
Human tumor cell lines were maintained in culture by regularly passaging them in 
appropriate culture media and growth conditions. Passaging cells is essential as 
failure to do so leads to reduced mitotic index and eventually cell death. Cultured 
cells upon attaining a confluency of 70-80% were passaged. Media was removed 
using a glass Pasteur pipette in a sterile cell culture hood and cells were washed 
with 5 ml of PBS. The cells were incubated with trypsin in the incubator (37oC/5% 
CO2) till they detached from the surface of the plate. Equal volume of fresh culture 
media was added to the trypsinised cells to prevent further action of trypsin. The 
cells were collected in a 15 ml falcon tube and centrifuged at 0.8 x g for 5 m, 
supernatant was removed using a glass Pasteur pipette and the pellet was 
resuspended in fresh culture media. New passages were made by adding the cells 
to fresh complete cell culture media in appropriate dilutions. The cell culture plates 
were incubated at 37oC/5% CO2 till they reached a confluency of 70-80%. 
Cell line Cell culture media Passaging ratio 
SW480 RPMI 1640 1:10 
SW620 RPMI 1640 1:10 
HeLa DMEM 1:8 
HCT116 McCoy’s 5a 1:10 
HT29 McCoy’s 5a 1:10 
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3.1.3 Counting and seeding cells for experiments 
Cells after trypsinisation were resuspended in fresh culture media and collected in a 
15 ml falcon tube and centrifuged at 0.8 x g for 5 m. The supernatant was discarded 
and the pellet was resuspended in fresh culture media. 10 µl of the suspension was 
added in the Neubauer chamber and the cells counted as per the instructions of the 
manufacturer. The resuspended cells were diluted in fresh culture media to obtain 
the required cell count.  
Plate type Volume used Cells seeded 
6 well 2 ml 100,000 
12 well 1 ml 50,000 
96 well 100 µl 8000 
 
3.1.4 Treatment of cells with chemotherapeutics 
Chemotherapeutics were dissolved in water/DMSO to attain a requisite stock 
concentration as prescribed by the manufacturer. The stock chemotherapeutics were 
dissolved in cell culture media before the treatment of the cells. The solubility, stock 
concentrations and working concentrations of the chemotherapeutics is listed below-  
    





5-FU DMSO 5 mM 5 µM-500 µM -20oC 
Gemcitabine Water 64 mM 5 nM-200 nM -20oC 
B02 DMSO 10 mM 50 µM -20oC 
Raltitrexed Water 7 mM 7nM-700 µM -20oC 
NCS Water 1 mg/ml 100 ng/ml +4oC 
Hydroxyurea Water 3 M 1mM -20oC 
UCN01 DMSO 10 mM 1 mM -20oC 
ZVAD DMSO 20 mM 20 µM -20oC 
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3.1.5 Reporter assay for assessing homologous recombination repair  
Homologous recombination repair is a DNA repair process employed by cells in the 
S/G2 phases of the cell cycle to repair double strand DNA breaks  
Principle of DRGFP assay 
The DRGFP plasmid contains a truncated GFP cassette on the N-terminal region, 
within which is located a restriction endonuclease site for the meganuclease, I-sce1.  
I-sce1 when co expressed along with the DRGFP plasmid, cleaves the plasmid 
producing a double strand break. If the break is repaired by non-homologous end 
joining pathway, functional GFP cassette is not produced and therefore the cell does 
not express GFP and can be confirmed by no fluorescence in flow cytometry. On the 
other hand, if the cells employ homologous recombination repair using the truncated 
GFP cassette near C-terminus, functional GFP cassette is restored. Therefore, the 
cells employing homologous recombination repair would express GFP which can be 
measured by flow cytometry (Figure 4.4b).  
100,000 HeLa cells were seeded per well in a 6 well cell culture plate. The cells were 
allowed to grow till they reached a confluency of ~ 80%. Lipofectamine 2000 based 
plasmid transfections were performed with DRGFP, DsRed and I-sce1 plasmids, as 
prescribed by the manufacturer. 4 h after transfection media was changed from the 
wells, wells washed and treated with 5 µM 5-FU/DMSO for 24 h. This was followed 
by 24 h of treatment with 100 ng/ml NCS. After the treatments, wells were washed 
with PBS and trypsinised. Following trypsinisation, cells were collected in a 2 ml 
Eppendorf TM tube and centrifuged at 0.8 x g for 5 m. The supernatant was removed 
and cell pellet was washed with PBS, centrifuged, suspended in PBS and the GFP 
positive cells were measured using Guava flow cytometer as per the instructions of 
the manufacturer.  
3.1.6 Reporter assay for assessing Non-homologous end joining 
The other repair pathway employed by a cell to repair the double strand breaks is 
the Non-homologous end joining (NHEJ).  
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Principle 
The NHEJ plasmid contains a GFP cassette, split into two non-functional sequences. 
Interspersed between these sequences is an exon AD, derived from mouse. The 
truncated GFP cassette at the N-terminus contains sequence recognized and 
cleaved by HindIII. The splice donor and acceptor sites are represented in the Figure 
4.4d. If the cell employs NHEJ to repair the DNA, transcript coding for functional 
GFP is transcribed. Therefore, cells employing NHEJ express GFP whereas the 
ones that do not employ NHEJ do not express GFP.  
100,000 HeLa cells were seeded per well in a 6 well cell culture plate. The cells were 
allowed to grow till they reached a confluency of ca 80%. Lipofectamine 2000 based 
plasmid transfections were performed with linearized NHEJ plasmid and DsRed as 
prescribed by the manufacturer. 4 h after transfection media was changed and the 
wells washed and treated with 5 µM 5-FU/DMSO for 24 h. This was followed by 24 h 
of treatment with 100 ng/ml NCS. The wells were washed with PBS and trypsinised. 
Following trypsinisation, cells were collected in a 2 ml Eppendorf TM tube and 
centrifuged at 0.8 x g for 5 m. The supernatant was removed and the cell pellet was 
washed with PBS, centrifuged, resuspended in PBS and the GFP positive cells were 
measured using Guava flow cytometer as per the instructions of the manufacturer.  
3.1.7 GFP measurements for HRR and NHEJ assays 
After the respective incubations and treatments, the cells were trypsinised, 
centrifuged at 0.8 x g, washed and resuspended in PBS. The samples were 
immediately measured for GFP expression using Guava easyCyteTM flow cytometer 
as per the instructions of the manufacturer. The GFP expression was normalized by 
dividing the GFP and DsRed positive cells with the total DsRed positive cells 
(internal normalization) followed by normalization to the DMSO control and plotted 
as a bar diagram.   
3.1.8 Transient siRNA transfections 
The length of the siRNA usually varies between 20-24 nucleotides. siRNA forms a 
complex with RISC and associated factors, binds to the target mRNA leading to its 
recognition and cleavage.  
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In order to transfect cells with siRNA, master mixes for siRNA and LF2000 were 
prepared. For transient transfections in a 12 well plate, 0.3 µl of siRNA (stock 50 µM) 
was dissolved in pre warmed cell culture media without any FCS or antibiotics and 
incubated at room temperature for 5 m. Simultaneously, LF2000 master mix was 
prepared by dissolving 2 µl LF2000 in 100 µl media and incubated at room 
temperature for 5 m. After incubation, the LF2000 master mix was added to the 
siRNA master mix and incubated for 20 m at room temperature. 200 µl of this mix 
was added per well along with 100,000 cells. The cells were incubated at 37oC / 5% 
CO2 for 16 h followed by exchange of media and treatment of cells with the 
chemotherapeutics.  
 
Plate type Volume of siRNA Final concentration 
12 well 0.3  µl 10 nM 
6 well 0.6 µl 10 nM 
96 well 0.03 µl 10 nM 
 
3.1.9 Propidium Iodide staining  
Propidium iodide (PI) staining is employed to gauge the cell cycle distribution. PI is a 
DNA intercalating agent and readily permeates into live cells. PI staining is 
proportional to the DNA content of a cell and therefore can be used to distinguish G1 
phase with 2X chromosomes from G2 phase (when DNA replication is complete) 
with 4X chromosomes. S phase typically lies between G1 and G2 and has staining 
intensity between G1 and G2 phases.  
In brief, SW480/HeLa cells were seeded in a 6 well plate and allowed to grow 
overnight a 37oC/5% CO2.  The cells were treated with 5 µM 5-FU for 24 h followed 
by treatment with 100 ng/ml NCS for 2, 8 and 24 h. Following the incubation times 
the cells were harvested using trypsin as described previously. The cells were 
centrifuged at 1 x g for 5 m. The supernatant was removed and cells washed once 
with PBS. The pellet was suspended in 500 µl PBS and fixed using 70% ethanol 
(added drop wise to final volume of 2 ml) overnight at 4oC. The fixed samples were 
centrifuged at 1 x g for 5 m followed by washing once with PBS. The pellet was 
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suspended in 200 µl of 0.5 mg/ml RNaseA and incubated at 37oC for 30 m. The 
samples were then diluted in PBS to attain a final cell count of 500 cells / µl and 
measured as per the instructions of the manufacturer.  
3.1.10 Cell proliferation assay 
Cell proliferation assay is used to study the effect of chemotherapeutics on cellular 
growth. There are many methods described in literature for cell viability assays like 
MTT assay, crystal violet assay etc.  
Cells were seeded in 96 well corning star 3603 plates and incubated at 37oC/5% 
CO2 for 24 h. They were treated with 5 µM 5-FU/DMSO/gemcitabine/MK2i for 24 h 
followed by 100 ng/ml NCS for 24 h. The wells were washed with PBS and fresh 
media was added. Cell confluency was measured using cyntellect CeligoTM 
automated cell cytometer every day at intervals of 24 h. Cell confluency denotes the 
total surface area covered by the cells in the wells and was analysed by the software 
provided from the cyntellect CeligoTM. 
 
3.2 Biochemistry 
3.2.1 SDS PAGE and Immunoblotting 
Sample preparation 
The cells after the respective treatments and incubations were harvested on ice 
using a cell scraper. The harvesting was done with the culture media and no 
washing was done prior to harvesting. The harvest was collected in an Eppendorf TM 
tube and centrifuged at 0.8 x g for 5 m. The supernatant was removed with the help 
of a syringe tip and vacuum. The pellet was suspended in PBS (to wash away 
excess culture media) and centrifuged at 0.8 x g for 5 m; PBS was removed as 
explained above. The pellet was suspended in appropriate volume of RIPA buffer. 
Protein estimation 
The samples suspended in RIPA buffer were centrifuged at 12000 x g for 10 m to 
pellet any cell debris. The protein was estimated using BCA kit from thermo scientific 
as described by the manufacturer. 5 µl of the protein sample was added to 40 µl of 
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the master reagent (reagent A: reagent B: 49:1). The samples were incubated at 
37oC for 30 m, followed by protein estimation using nano-drop at 562 nm.  
SDS-PAGE  
12 % SDS PAGE gels were cast with ingredients as shown in the table below. The 
samples were loaded in the pockets in equal concentrations. The gels were run at a 
constant voltage of 80 V. 
Immunoblotting  
The immunoblotting buffer was pre cooled at 4oC. Whatman filter papers were cut 
and soaked in immunobloting buffer along with sponges. The nitrocellulose 
membrane was cut in 8X8 cm size and was soaked transiently in the immunoblotting 
buffer. The apparatus for immunoblotting was set up as instructed by the 
manufacturer and a voltage of 100 V was applied for 1h 30 min at 4oC. After the 
transfer of proteins, the nitrocellulose membrane was incubated in Ponceau S and 
scanned. The nitrocellulose membrane was washed with water for 10 m to remove 
the Ponceau S stain. Next, the membrane was blocked in 5% BSA for one hour at 
room temperature. The membrane was cut in to strips based on the molecular 
weight as indicated by the PAGE markerTM followed by incubation of the membrane 
strips in the primary antibodies overnight at 4oC. The membrane strips were washed 
with TBST two times for fifteen m each at room temperature. After washing, the 
membranes were incubated in secondary antibodies for one hour at room 
temperature. The strips were washed again with TBST two times at room 
temperature and then developed with ECL from Millipore. The images of the 
membranes were taken using Intas imageTM.  
3.2.2 Chromatin fractionation 
DNA in a cell is wound around histone octamers. The complex of DNA and the 
associated proteins is called chromatin. In the absence of DNA damage, DNA repair 
proteins are localized in the cytoplasm or in nucleus but are not associated with the 
DNA. Upon DNA damage, these proteins relocalize and associate with chromatin to 
perform DNA repair. Chromatin fractionation is a technique employed to specifically 
collect the proteins on the chromatin. The soluble fraction contains the unbound 
proteins, including the cytoplasmic proteins.  
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200,000 SW480 cells were seeded in 6 well plates for 24 h and incubated at 
37oC/5% CO2. Cells were treated with 5 µM 5-FU/DMSO for 24 h followed by 100 
ng/ml NCS for 24 h. Treated cells were harvested at different time points and 
collected in an Eppendorf tube. Cells were washed twice with PBS, resuspended in 
200 µl of buffer A with 0.1% Triton-X-100 and incubated on ice for 8 m. The samples 
were centrifuged at 1300 x g for 5 m and the supernatant (S1) was collected. Pellet 
(P1) was washed with buffer A and suspended in buffer B for 3 m on ice. P1 was 
centrifuged at 1700 x g for 5 m, the supernatant was collected and the pellet was 
resuspended in buffer B. Laemlli buffer was added and the samples boiled at 70oC 
for 20 m.  
 
3.3 Molecular biology 
3.3.1 Plasmid preparation  
Chemically competent E.coli strain, DH10B was incubated with 1 µl of desired 
plasmid for 30 m on ice. Heat shock was applied by incubating the cells at 37oC for 
10 m followed by immediate transfer on to ice. The bacterial cells were plated on 
agar plates containing either ampicillin (100 mg/ ml) or kanamycin (50 mg/ ml) and 
incubated at 37oC overnight. Colonies were picked and inoculated in 2YT medium 
supplemented with either ampicillin or kanamycin overnight at 37oC. The culture was 
centrifuged at 5,000 x g for 10 m and the supernatant was discarded. The pellet was 
first resuspended in cell resuspension solution and then incubated for 3 m with cell 
lysis solution. Post lysis, neutralization buffer was added and incubated for 3 m at 
room temperature. The lysate was centrifuged at 15000 x g for 15 m and the clear 
supernatant was passed through the clearing column. The binding column was 
washed with 20 ml of wash solution and the bound DNA was eluted with the sterile 
water. The plasmid DNA was collected in an Eppendorf tube, concentration 
measured and stored at -80oC.  
3.3.2 Total RNA isolation 
200,000 cells were seeded in 6 well plates and incubated at 37oC/5% CO2 for 24 h. 
Cells were treated with 5 µM 5-FU/DMSO for 24 h followed by 100 ng/ml NCS for 24 
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h.  After the treatments, cells were trypsinised and collected in 2 ml Eppendorf tubes 
and centrifuged at 0.8 x g for 5 m. Supernatant was removed and the pellet washed 
with PBS. The pellet was resuspended in 600 µl TrizolTM and incubated at room 
temperature for 5 m. To separate the phases, 120 µl of chloroform was added to the 
samples and incubated at room temperature for 3 m with vigorous shaking. The 
samples were centrifuged at 15,000 x g for 15 m at 4oC. The aqueous phase, 
containing RNA was collected and purified with 500 µl isopropanol. Samples were 
thoroughly mixed, incubated for 10 m at room temperature and centrifuged at 15,000 
x g for 10 m at 4oC. The pellet was washed with 75% ethanol and the finally 
dissolved in water. To eliminate protein impurities the RNA was precipitated with 300 
mM sodium acetate and 50% ethanol. The pellet was resuspended in water, 
concentration and purity measured using nanodrop. RNA was stored at -80oC for 
further studies.  
 
3.4 Quantitative Immunofluorescence  
In a 96 well BD falconTM plate, 8000 cells were seeded and incubated at 37oC/5% 
CO2 for 24 h. The cells were treated with 5 µM 5-FU/DMSO/RTXD/gemcitabine for 
24 h followed by 100ng/ml NCS for 2, 8 or 24 h. The cells treated with DMSO served 
as negative control. Following the treatment, the cells were fixed with 4% PFA at 
room temperature and permeabilized with 0.5% Triton X 100. Blocking was done 
with 5% BSA at room temperature for 30 m. Wells were incubated with 100 µl 
primary antibodies (γ-H2AX) diluted in 3% BSA at appropriate concentrations, 
overnight at 4oC. The wells were washed with blocking solution before incubation 
with 70 µl secondary antibodies (Alexa 488 or Alexa 594), diluted in 3% BSA, for 1 h 
at room temperature in dark. The cells were counterstained with Hoechst 33342 
along with the secondary antibody incubation. 200 µl PBS was added in each well 
and the plate was covered with aluminum foil and fluorescence intensity 
measurements were made using the BD pathway 855 automated microscope.  
Fluorescence intensity was measured from ROI (region of interest) defined by the 
software limiting the reading to the nuclei. The average fluorescence intensity was 
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determined and used for plotting histograms. In each of the experiments a minimum 
of 1000 ROI’s were chosen for plotting the histograms.    
 
3.5 Confocal microscopy 
SW480 cells were grown on coverslips in a 24 well cell culture plate. Cells were 
treated with 5 µM 5-FU/DMSO for 24 h followed by treatment with 100 ng/ml NCS for 
2, 8 or 24 h. Cells treated with DMSO were used as negative controls. Cells were 
fixed with 4% PFA at room temperature and permeabilized with 0.5% Triton X 100. 
Blocking was done with 3% BSA in PBS for 30 m at room temperature. Samples 
were incubated with primary antibodies, diluted in 3% BSA with appropriate 
concentrations, overnight at 4oC. Coverslips were washed with PBS and incubated 
with secondary antibodies, diluted in 3% BSA, for 1 h at room temperature in dark. 
Coverslips were washed with PBS and mounted on slides. The cells were 
counterstained with Hoechst 33342. The images were taken with Carl Zeiss LSM 
510 meta at 63X. The RPA2 foci were quantified using FociCounter, free software 
available at http://focicounter.sourceforge.net/ (accessed on 1-11-2014).  
 
3.6 Gamma radiation exposure of cells 
Cells to be irradiated were grown in cell culture flasks and incubated at 37oC/5% 
CO2 for 24 h. The cells were treated with 5 µM 5-FU/DMSO for 24 h. After the 
respective treatments the flasks were irradiated with 5 Gy of gamma radiation. The 
cells were incubated at 37oC/5% CO2 and harvested at 2, 8 or 24 h post irradiation.  
 
3.7 BrdU assay for ssDNA  
8000 cells were seeded in a 96 well plate and incubated for 24 h at 37oC/5% CO2. 
Cells were incubated with BrdU for 24 h, treated with 5 µM 5-FU/DMSO for 24 h 
followed by treatment with 100 ng/ ml NCS for 24 h. Following the treatments the 
cells were pre extracted for 5 m, fixed with 4% PFA, washed with PBS and blocked 
with 5% BSA. Cells were incubated for 1 h at room temperature with BrdU primary 
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antibody diluted in 5% BSA. Post incubation, cells were washed with PBS and 
incubated with secondary antibody in dark for 1 h at room temperature. Following 
incubation with secondary antibody, cells were washed with PBS; plate covered with 
aluminum foil and the fluorescent intensity was measured using BD automated 
fluorescence microscope. 
  
3.8 EdU assay 
8000 cells were seeded in a 96 well plate and incubated for 24 h at 37oC/5% CO2. 
Cells were treated with 5 µM 5-FU/DMSO for 24 h followed by treatment with 100 
ng/ ml NCS for 24 h. 2 h prior to fixation, cells were treated with 10 mM EdU. Post 
treatment, cells were fixed with 4% PFA, washed with PBS, permeabilised with 0.5 
% Triton X 100 and blocked with 5% BSA. Cells were incubated with Click iTTM 
reaction master mix for 30 m at room temperature. Cells were washed with PBS and 
incubated with Hoechst for 45 m at room temperature in dark, washed with PBS. 200 
µl PBS was added to each well and the plate was covered with aluminum foil to 
avoid bleaching of fluorescence. The fluorescent intensity was measured using BD 
automated fluorescence microscope and the total percentage of cells with EdU 
incorporation were plotted to estimate the S phase population. 
 
3.9 Statistical analysis 
Statistical calculations were performed using graph pad PrismTM. Statistical 
significance was calculated for at least 3 independent biological experiments using 
two tailed student’s t-test. Significance was assumed for p value lower than 0.05, 
asterisk were used to denote the significance in the figures: * p<0.05, **p<0.01, 
***p<0.001.
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4 Results 
4.1 5-FU and NCS combination results in persistent γ-H2AX 
Chemoradiotherapy of CRC involves bolus 5-FU treatment followed by radiotherapy. 
In order to elucidate the molecular mechanisms behind the synergisms between 5-
FU and γ-radiation, a combination of 5-FU and NCS was used in CRC cell lines. 
Phosphorylated H2AX is a known marker for assessing double strand breaks in 
cells; we therefore used it to evaluate the DNA damage induced during our 
treatments. Further, NCS and γ-radiation are known to induce DNA double strand 
breaks.  
Since gamma-irradiation depends on a source, we replaced this treatment by NCS. 
Our goal was to set up an experimental system that allows us to faithfully 
recapitulate the treatment of patients. In the most successful treatment regimens, 
patients are first treated with 5-FU, followed by irradiation. In our studies, we 
replaced the patients’ tumors with CRC cell lines. These cells were first treated with 
5 µM 5-FU (unless specified). Secondly, we exposed the cells to 100 ng/ml NCS 
(unless specified), thus approximating gamma irradiation. Subsequently, the 
accumulation of γ-H2AX was monitored as readout for the DNA damage response. 
In order to determine the combined effect of 5-FU and NCS on the DNA damage 
response in colorectal cancer cells, we treated cells with a combination of 5-FU and 
NCS at concentrations of 5 µM and 100 ng/ml respectively. We had performed 5-FU 
titrations which confirmed synergism with NCS at a low concentration of 5 µM (data 
not shown).  
Immunoblotting of samples treated with 5-FU in combination with NCS showed a 
large accumulation of γ-H2AX that persisted for 24 h post-NCS treatment in HeLa 
and SW480 cells (Figure 4.1A and 4.1B). This indicated that the DNA damage 
induced 2 h post NCS treatment remained unrepaired.  However, in both cases 
treatment with 5-FU alone, did not show any significant accumulation of γ-H2AX at 
the indicated time points. NCS treatment led to increase in γ-H2AX levels at 2 h, but 
declined over time indicating DNA repair (Figure 4.1). We next performed 
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quantitative immunofluorescence (see 3.4) and quantified the fluorescent intensity in 
SW480 cells. Average γ-H2AX intensities shown as box plots reaffirm the 
observation of persistent γ-H2AX in response to 5-FU and NCS (Figure 4.1C).  
We next used the constraint function of the BD attovisionTM image analysis software 
to select nuclei with γ-H2AX intensity greater than 800 (arbitrary units) and found 
that combination treatment of 5-FU and NCS causes 80-90% cells to have high γ-
H2AX (Figure 4.1D). The constraint was chosen by us and the reason for this 
selection was to eliminate γ-H2AX arising from spontaneous DNA damage in the 
cells. It is basically used to remove any background levels of fluorescent intensity. 
NCS induced damage was evident in about 40% cells whereas the 5-FU treatment 
did not cause accumulation of high levels of γ-H2AX. These experiments proved that 
5-FU pretreatment not only sensitizes the cells to NCS but also causes persistent γ-
H2AX in a majority of the cells.   
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Figure 4.1 5-FU and NCS in combination cause persistent γ-H2AX. 
(A) SW480, (B) HeLa cells were treated with 5 µM 5-FU/DMSO for 24 h followed by 
treatment with 100 ng/ml NCS for 2, 8 and 24 h while continuing the 5-FU treatment. 
The cells were harvested and whole cell lysates were analyzed by immunoblotting. 
Antibodies to γ-H2AX were used to quantify the extent of the DNA damage 
response, whereas β-actin was detected as a loading control. (C) Following the 
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min at room temperature, and then stained for γ-H2AX. Automated microscopy and 
image analysis were performed using the BD pathway system, and the results are 
shown as a box plot (n=3) as detailed in section 3.4. *= p<0.05: **= p<0.01 
(Student’s t-test) (D) Percentage of cells with greater than 800 arbitrary units 
intensity, as determined by the BD AttovisionTM software, is plotted for each 
treatment. The columns represent the mean of three independent experiments; the 
error bars represent the standard error of the mean. 
 
4.2 NCS and γ-radiation produce similar cellular effects on the kinetics 
of γ-H2AX accumulation 
To verify whether NCS and γ-radiation have similar effects on the kinetics of γ-H2AX 
accumulation and removal particularly to see if the immediate increased 
accumulation is sustained in case of cells pre-treated with 5-FU. To this end, we 
treated SW480 cells with 5-FU and exposed them to 5 Gy of γ-radiation. This γ-
radiation dose was chosen as it correlated with the NCS concentrations used in the 
study. As observed previously with NCS (Figure 4.1), combination of 5-FU and γ-
radiation led to persistence of γ-H2AX (Figure 4.2), however treatment with γ-
radiation alone, showed an accumulation of γ-H2AX 2 h post radiation that 
diminished over time indicating repair of the damaged DNA. This observation was 
similar to that with NCS indicating similar cellular response.  
 
 
Figure 4.2 Kinetics of γ-H2AX accumulation is similar between NCS and γ-H2AX. 
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SW480 cells were treated with 5 µM 5-FU/DMSO for 24 h followed by 5 Gy of irradiation 
while continuing the 5-FU treatment. Cells were harvested 2 h or 24 h post-irradiation and 
whole cell lysates were analyzed by immunoblotting using the indicated antibodies. 
Antibodies to γ-H2AX were used to quantify the extent of the DNA damage response, 
whereas β-actin was detected as a loading control. 
 
We next looked for the effect of radiation on the total protein levels of two key DNA 
repair protein Rad51 and Ku70, but did not find any significant changes indicating 
that the overall levels if these proteins remain the same even after the treatments. 
This together with the observation that there was no cleaved caspase 3, indicating 
absence of apoptosis, confirmed the sole contributor of γ-H2AX to be DNA damage 
response. This therefore proves that the kinetics of γ-H2AX accumulation in 
response to γ-radiation is similar to NCS and validates its use as a substitute to γ-
radiation. 
 
4.3 5-FU and NCS in combination reduce cell proliferation and survival  
In order to examine the effect of combination therapy on cell proliferation, we 
performed the long term cell proliferation assay on CRC cell lines. Cell proliferation 
assays elucidate the effect of drugs on cells over a long period of time, telling us the 
consequences of the treatment in a long term. 5 µM 5-FU was added on day2 
followed by 100 ng/ml NCS on day3. Following this the media was changed every 2 
days. This treatment severely impaired the cell proliferation (Figure 4.3a), however 
treatment with 5-FU alone reduced the rate of cell proliferation but cells recovered 
from initial lag to resume proliferation (Figure 4.3a). NCS on the other hand had no 
significant effect on the cell proliferation. This therefore confirmed that combination 
of 5-FU and NCS severely impairs the proliferation and affects the cell survival.   
We next used lower NCS concentrations (10 and 20 ng/ml) to verify if the synergistic 
effect of the combination treatment depends on the initial DNA damage induced by 
NCS. As seen in the (Figure 4.3b) combination of 5-FU with 10 ng/ml NCS did not 
show any synergistic effect; however treatment with 20 ng/ml NCS showed 
synergistic effects as observed earlier with 5 µM 5-FU and 100 ng/ml NCS, 
indicating that this is the minimum NCS concentration at which synergism with 5-FU 
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is seen. Furthermore, at high 5-FU concentrations of 100 µM, cell survival decreased 
drastically (Figure 4.3c) hindering any further synergism studies.  
We also investigated effects of combination treatment on HT-29, a CRC cell line that 
is known to be radioresistant. As shown by the cell survival in (Figure 4.3d) we found 
HT-29 to be radioresistant, but surprisingly very sensitive to 5-FU even at 5 µM; 
therefore we did not pursue further synergism studies with these cells. These results 
indicated that the combination of 5-FU (5 µM) with NCS (100 ng/ml) severely 
impaired the cell proliferation and this effect is dependent on the concentration of 5-
FU as well as NCS and also depends on cell lines being studied. 
Taken together our results indicate that combination of 5 µM 5-FU and 100 ng/ml 
NCS severely impair the cell proliferation and reduce the cell survival in SW480 
cells. Use of higher concentrations of 5-FU (100 µM) reduce the survival of SW480 
cells, possibly leading to apoptosis. We could also show that the synergism between 
5 µM 5-FU and NCS begins at the concentration of 20 ng/ml of NCS. On the other 
hand HT-29 cells were fund to be very sensitive to 5-FU and exhibited almost no 
survival with 5 µM 5-FU. These results also indicate that the persistent γ-H2AX 
observed in the case of cells treated with a combination of 5-FU and NCS indicate 
severe DNA damage which affect their proliferation and if unrepaired for longer 
duration may lead to cell death.  
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Figure 4.3 5-FU and NCS in combination severely impairs cell proliferation in 
colorectal cancer cells.  
Cells were treated with 5 µM 5-FU/DMSO on day 2 followed by 100 ng/ml NCS on day 3; 
cell confluency was measured every day using CyntellectTM celigo as described in 3.1.10. 
SW480 cells treated with (a) 5 µM 5-FU and/ or 100 ng/ml NCS, (b) 5 µM 5-FU and 10 or 20 
ng/ml NCS, (c) HT-29 cells treated with 5 µM 5-FU and/ or 100 ng/ml NCS (d) SW480 cells 
treated with 100 µM 5-FU and/or 100 ng/ml NCS. 
 
4.4 5-FU reduces the ability to perform HRR but does not affect NHEJ  
We next wondered why does the combination of 5-FU and NCS induces such a 
catastrophic effect on cell survival and DNA damage as seen by the persistently high 
γ-H2AX. We knew that NCS and γ-radiation primarily induce DSB in DNA; though 
with different molecular mechanisms. We had previously observed that cells treated 
with 5-FU and NCS show persistent γ-H2AX (Figure 4.1), indicating a defect in DNA 
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DSB repair in these cells. Since a mammalian cell can employ either HRR or NHEJ 
to repair DSBs, we investigated these pathways using plasmid based reporter 
assays in HeLa cells (section 3.1.5 and 3.1.6). HeLa cells were chosen because of 
the ease of transfection and high transfection efficiency. We had observed the 
persistent γ-H2AX in HeLa cells too and therefore deemed it to be a safe model 
system to perform the assays.  
DRGFP assay (Figure 4.4b) involves transfection of DRGFP plasmid along with 
pCBASceI in cells along with DsRed that was used to normalize transfection 
efficiency.  The DRGFP plasmid has an I-sceI restriction endonuclease site and 
therefore upon expression of I-SceI produces a double strand break in the plasmid. 
Apart from the restriction site, it has two truncated GFP cassettes that do not 
express GFP.  If the cell repairs the DNA double strand break using the iGFP as a 
template, a functional GFP cassette is formed on the plasmid. Therefore, cells 
employing HRR express GFP while the ones that do not use HRR to repair the break 
do not express GFP.   We employed DRGFP assay to assess HRR in cells treated 
with 5-FU and NCS and found that 5-FU reduced the efficiency of HRR. NCS on the 
other hand did not affect the HRR (Figure 4.4a). The combination of NCS with 5-FU 
also showed a reduction; however, no significant effect was observed due to NCS 
treatment in these samples. We therefore concluded that 5-FU alone is responsible 
for the reduction of homologous recombination repair in cells.  
We next employed a plasmid based reporter assay to assess NHEJ in mammalian 
cells. The NHEJ reporter plasmid has a split GFP cassette neither of which produces 
GFP (section 3.1.6). An intron Ad is present between the split GFP cassettes and 
has a HindIII restriction endonuclease sites. Repair of the double strand breaks by 
NHEJ allows the cell to transcribe a functional GFP and therefore only the cells 
employing NHEJ will express GFP while others will not.  
As shown in Figure 4.4c, 5-FU did not significantly reduce the NHEJ either alone or 
in combination with NCS; NCS also did not show any effect on the NHEJ. In 
conclusion, 5-FU pretreatment reduces cells capacity to perform HRR while NHEJ is 
not affected. This result also explains the persistence of γ-H2AX in cells pretreated 
with 5-FU and exposed to NCS. The cells treated with 5-FU have a compromised 
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HRR and when challenged with NCS cannot repair the double strand breaks leading 
to persistent γ-H2AX. On the other hand persistent γ-H2AX is not seen in 5-FU 
treated cells as 5-FU alone does not induce such high levels of DNA double strand 
breaks. NCS treated cells expectedly show a reduction in γ-H2AX levels as the 
treatment does not affect the homologous recombination repair.   
 
Figure 4.4 5-FU reduces the homologous recombination repair but does not affect the 
non-homologous end joining.  
(a) HeLa cells were transfected with the DRGFP, IsceI and DsRed plasmid followed by 
treatment with 5-FU/DMSO for 24 h and then with NCS for 24 h. GFP positive cells were 
quantified using guava easycyteTM flow cytometer. (b) Schematic representation of the 
principle of DRGFP assay, (c) linearized NHEJ plasmid along with DsRed plasmid were 
transfected in HeLa cells followed by treatment with 5 µM 5-FU/DMSO for 24 h and then 
with 100 ng/ml NCS for 24 h. GFP positive cells were quantified using guava easycyteTM flow 
cytometer. (d) Schematic representation of the principle of NHEJ assay. Error bars indicate 
standard errors of the mean. For normalization methods please refer section 3.1.7.  
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4.5 5-FU causes S phase arrest  
We had observed that the cells treated with 5-FU had a reduced capability to 
perform HRR (Figure 4.4). We next asked if this was a result of cell cycle arrest in 
G1 phase. The activation of the DSB repair pathways is dependent on the cell cycle 
phase with HRR most active in S/G2 phase while NHEJ is favored in G1 phase. 
Since we had observed that HRR was reduced in the presence of 5-FU, this could 
have been due to accumulation of cells in phases of the cell cycle that do not permit 
HRR. We therefore investigated whether 5-FU might cause arrest in G1. In light of 
our observations on HRR (Figure 4.4), we investigated the effect of 5-FU and NCS 
on cell cycle using Propidium iodide (PI) staining. Propidium iodide intercalates in 
DNA and can be used as a measure to determine the quantity of DNA and therefore 
the phase of cell cycle. Cells in G1 phase have 2N DNA content while in G2 phase 
they double their DNA content to 4N. The cells in S phase have DNA content in 
between 2N and 4N. 5 µM 5-FU treatment led to S phase arrest in 80% of the cells 
(Figure 4.5c, 4.5e, and 4.5f) while NCS alone causes a strong G2 arrest (Figure 4.5d 
and 4.5e). Interestingly, the combination of 5-FU and NCS also exhibited S phase 
arrest in similar percentage of cells without any additive effect of NCS (Figure 4.5b, 
4.5e, and 4.5f). Taken together, we conclude that 5-FU does not induce detectable 
G1 arrest. Thus, the reduction of HRR that we had observed cannot simply be 
ascribed to a shift in the cell cycle. 
We next performed EdU incorporation assay, to determine the proportion of cells 
specifically in S phase. EdU is incorporated into DNA during replication and the 
alkyne group in EdU is then detected using fluorescent azides by click chemistry. 
The fluorescent intensity was then quantified using the BD pathwayTM automated 
microscope.  The advantage of this method over BrdU staining is that the samples 
do not have to be denatured before the measurements. Since only actively 
replicating cells can incorporate EdU, this can be used to quantify the cells in S 
phase.  
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5 µM 5-FU treatment showed 80-90% cells in S phase (Figure 4.5f), both with and 
without NCS treatment while there were fewer than 20-25% NCS treated cells in S 
phase corroborating our PI staining results. 
Taken together, our results indicate that 5-FU treatment induces an S phase arrest 
in majority of the cells while NCS treatment causes a predominant G2 arrest. 
Interestingly, both S and G2 phases are favorable for HRR and we still saw a 5-FU 
induced reduction of HRR (Figure 4.4b) indicating that arrest in unfavorable cell 
cycle phase is not the reason for the reduced homologous recombination repair in 
response to 5-FU.   
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Figure 4.5 5-FU causes S phase arrest. 
SW480 cells were treated with DMSO/5-FU (5 µM) for 2,8 and 24 h followed by treatment 
with 100 ng/ml NCS for 24 h. Cell cycle distribution was analyzed using PI staining , (a) 
DMSO, (b) 5-FU + NCS, (c) 5-FU, (d) NCS. The peak on the left of the histogram represents 
G1 phase while the peak on the right represents G2 phase. The area between these two 
peaks represents S phase. (e) Quantification of cell cycle distribution was done using 
ModfitTM Verity software house (f) SW480 cells were treated with DMSO/5-FU (5 µM) for 24 
h followed by treatment with NCS for 24 h. 2 h prior to the addition of the drugs cells were 
treated with 15 µM EdU. Samples were fixed with 4% PFA followed by permeabilisation with 
0.5% triton-x-100 for 15 m. After blocking with 5% BSA samples were incubated with 
primary antibody for 1 h in dark. After washing, samples were incubated with Alexa 488 HCS 
for 45 m in dark. EdU positive cells were quantified using BD AttovisionTM as described in 
section 3.8.  Error bars indicate the standard error of the mean.  
 
4.6 Existence of DSB repair proteins on chromatin indicates ongoing 
repair in cells treated with 5-FU and NCS  
We had previously observed that 5-FU treatment compromises the cells ability to 
perform homologous recombination repair (Figure 4.4). One reason for the reduction 
in the repair processes could be the lack of recruitment of repair proteins onto 
chromatin. In order to understand the molecular basis for the reduced homologous 
recombination repair in 5-FU treated cells, we checked for the recruitment of several 
known repair proteins like RPA, Rad51 and Ku70.  
We first employed chromatin fractionation, a technique that is used to separate 
proteins bound to chromatin specifically from the soluble proteins. The presence of 
proteins on chromatin would indicate that the upstream repair signaling processes 
are intact, and the cell has the requisite repair machinery to carry out the DNA 
repair. We found that, 2 h post NCS treatment, combination of 5-FU and NCS led to 
minor increase in Rad51 (a key protein involved in HRR, section 1.9.2) recruitment 
while 5-FU alone did not affect its recruitment (Figure 4.6f).  However; 24 h post 
NCS treatment, combination treatment caused a marked increase in Rad51 
recruitment to the chromatin, with 5-FU alone also showing substantial recruitment 
(Figure 4.6f). At both the time points NCS alone did not show any significant 
recruitment of Rad51. This confirmed that in response to DNA damage induced by 
NCS in 5-FU pretreated cells Rad51 recruitment is not affected.   
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Next, we looked at RPA2 recruitment which showed an interesting trend, with 5 µM 
5-FU treatment causing a significantly higher enrichment from 2 to 24 h as compared 
to combination treatment. However, NCS showed a reduction in the RPA2 levels on 
chromatin at 24 h time point.  Treatment with 5-FU and/or NCS did not show any 
effect on the recruitment of Ku70, a protein involved in NHEJ repair (Figure 4.6f).  
We then employed immunofluorescence staining and quantified RPA2 foci in 5-FU 
and NCS treated cells, and found that 5-FU pretreatment led to a very strong and 
rapid recruitment (2 h post NCS treatment) compared to 5-FU and NCS alone 
treated cells (Figure 4.6 a-e).  
In conclusion, 5-FU and/or NCS do not affect the recruitment of the repair proteins 
onto chromatin and 5-FU pretreatment accelerates the RPA2 foci formation 
indicating the severity and extensiveness of the induced DNA damage. As RPA 
recruitment is a sign of presence of ssDNA, that can arise due to end resection 
during HRR, we can confirm that indeed the signaling upstream to activate the repair 
proteins for recruitment is intact and the process of repair proteins coming to the site 
of DNA damage are also functioning.  This also indicates that treatment with 5-FU 
does not affect the recruitment of repair proteins and therefore rules out the 
hypothesis that the reduction in HRR observed in response to 5-FU occurs due to a 
reduction in the repair proteins on chromatin.  
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Figure 4.6 Recruitment of repair proteins in response to 5-FU and NCS. 
SW480 cells were treated with (a) DMSO, (b) 5-FU (5 µM)+NCS (100 ng/ml), (c) 5-FU (5 
µM), and (d) NCS (100 ng/ml); for 2, 8 and 24 h. Cells were fixed with 4% PFA for 15 m 
followed by blocking and incubation with RPA2 overnight at 4oC. Next, cells were washed 
with blocking solution and incubated with Alexa 488 goat-anti-mouse for 1 h in dark. The 
images were taken using LSM 510 meta (e) RPA2 foci were quantified using FociCounter 
and percentage of RPA2 positive cells were plotted. Error bars indicate the standard error of 
the mean. (f) SW480 cells were fractionated into chromatin and soluble fractions. The cells 
were harvested 2 h or 24 h post NCS treatment, fractionated into chromatin and soluble 
fractions as described in 3.2.2. The samples were analyzed by immunoblotting using 
indicated antibodies.  
 
4.7 Ribonucleotide supplementation rescues cells from the persistent 
γ-H2AX 
Our first hypothesis that reduction in HRR may be caused due to impaired repair 
protein recruitment was proved false (Figure 4.6). Since, HRR requires active DNA 
synthesis, we therefore asked if nucleotide deprivation due to TS inhibition by 5-FU 
could be causing the observed reduction in HRR. 5-FU treatment 5-FU acts as an 
anti-cancer chemotherapeutic by causing DNA and RNA damage and TS inhibition 
(section 1.4.3). TS produces dTMP required for DNA synthesis and its inhibition 
causes nucleotide pool disruption.  
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To this end, we supplemented cells with ribonucleotides wondering if this would 
allow cells to repair the damaged DNA as they will have the substrates to carry 
forward the DNA synthesis. As shown earlier, 5-FU alone is capable of reducing 
HRR (Figure 4.5a), we therefore used a high 5-FU concentration (100 µM) to 
increase the DNA damage in cells. The high 5-FU concentration increased the 
accumulation of γ-H2AX accompanied by apoptosis, as indicated by cleaved 
caspase 3. In corroboration of the aforementioned hypothesis, we found that 
supplementing ribonucleotides markedly decreased the accumulation of γ-H2AX and 
cleaved caspase 3.  This indicates that the 5-FU generated reduction in HRR 
efficiency depends on its ability to inhibit TS (Figure 1.7).  As we had already ruled 
out the effect of 5-FU on the recruitment of repair proteins as a possible cause of the 
reduction in the lack of nucleotides appears to be the only reason for the reduction of 
HRR and therefore the persistent γ-H2AX in cells.    
 
 
Figure 4.7 Ribonucleotide supplementation reduces the DNA damage and apoptosis 
in 5-FU and NCS treated cells.  
SW480 cells were treated with 100 µM 5-FU/DMSO for 24 h followed by treatment with 100 
ng/ml NCS and/or ribonucleotides (300 mM of each ribonucleotide) for 24 h. Cells were 
harvested and whole cell lysates were analyzed by immunoblotting. Immunoblots showing 
marked reduction of γ-H2AX accumulation in cells treated with a combination of 5-FU and 
NCS or 5-FU alone. AM is a sample treated with cis-platin and served as a positive control 
for apoptosis. Cleaved caspase 3 was used to detect apoptosis and β-actin served as a 
loading control.  
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4.8 Comparison of RNA expression of repair proteins in tumor and 
mucosa 
We next evaluated the m-RNA expression of repair proteins in human tumors, to 
check if the expression of repair proteins is affected in tumors. For this purpose we 
collaborated with Prof. Tim Beißbarth (Department of Medical Statistics, University of 
Göttingen).  The analysis was performed by Dr. Jerzy Dyczkowski based on data set 
generated by Dr. Jochen Gaedcke (UMG, Göttingen). The data set was derived from 
colorectal cancer patients undergoing preoperative therapy. Though the patients 
were administered 5-FU based regimens, information on the drug cocktail and 
responses for all the patients were not available.  
Data set was part of the larger microarray set obtained from Jochen Gaedcke. It 
contains samples of colorectal tumour and healthy mucosa from 181 patients, which 
were analysed by Agilent microarrays. Gene expression was normalized and the 
highest expressed probe was used. Differential expression was analysed by by t-
test. Nevertheless, the analysis revealed that proteins involved in HRR namely 
Rad51 (Figure 4.8a), and BRCA2 (Figure 4.8b) are overexpressed in tumors 
compared to normal mucosa and the proteins involved in NHEJ namely XRCC5 
(Figure 4.8c) and XRCC6 (Figure 4.8d) also were overexpressed. The expression 
levels indicate the importance of DSB repair pathway for tumors. However, the data 
set did not allow us to correlate the expression pattern with the benefits of regimens 
used. In any case, the overexpression of the proteins involved in HRR indicates the 
reliance of tumors on this pathway. 
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Figure 4.8 Tumors overexpress components of HRR and NHEJ. 
Analysis of expression profiles between tumors and mucosa was performed using Gaedcke 
data set by Jerzy Dyczkowski (Department of Medical Statistics, University of Göettingen). 
Expression of (a) Rad 51, (b) BRCA2, (c) XRCC5, (d) XRCC6 in human colorectal tumors vs 
healthy mucosa shown as a boxplot. Refer to text for the method and analysis. n= number of 
patients analyzed in each set.  
 
4.9 TS inhibition does not synergize with NCS to induce DNA damage 
From our earlier finding, that lack of nucleotide substrates was causing reduction in 
HRR efficiency upon 5-FU treatment (Figure 4.7), we decided to deplete cells of TS 
by knockdown or pharmacological inhibition by Raltitrexed™ (RTXD). As described 
earlier, TS affects the dNTP pools, we therefore speculated that TS knockdown 
should synergize with NCS treatment like 5-FU.  So we asked ourselves the 
question, is the inhibition of TS by 5-FU sufficient to reduce the HRR or the other 
functions of 5-FU, namely DNA and RNA damage also important for compromising 
the HRR?  We again looked for persistent γ-H2AX as a marker for the extent of DNA 
damage.    
TS depletion combined with NCS treatment, did not show any synergism (Figure 
4.9a) with respect to γ-H2AX accumulation and neither the pharmacological 
inhibition showed any synergism with NCS. Different concentrations of RTXD were 
used (700 µM to 7 nM) to identify synergisms between TS inhibition and NCS 
treatment (Figure 4.9b). Interestingly, in none of these concentrations could we see 
any synergisms between RTXD and NCS. This pointed to the fact that synergisms 
observed with 5-FU were not due to TS inhibition alone.  
But to be absolutely certain that TS depletion or inhibition is not the only reason for 
reduced HRR seen with 5-FU, we depleted TS using siRNA in the SW480 cells and 
asked if the treatment with NCS will cause persistent γ-H2AX. We observed that 
depletion of TS followed by treatment with NCS did not produce persistent γ-H2AX 
as was seen with 5-FU (Figure 4.9a). Interestingly, the cells treated with scrambled 
siRNA and NCS also showed γ-H2AX and this can be attributed to the lipofectamine 
based transfections which are known to stress the cells. This therefore proves that 
inhibition of TS is not the only reason for reduced HRR.     
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We next studied the effect of 5-FU on TS knockdown wondering if the lack of TS 
would render cells more sensitive or resistant to 5-FU. Since, 5-FU inhibits TS, one 
possibility could be that the effect of 5-FU would be greatly reduced in the absence 
of its substrate, while the other possibility could be, greater misincorporation of the 5-
FU metabolite FdUTP leading to more DNA damage. Surprisingly, we found that in 
the absence of TS, 5-FU treatment increased the γ-H2AX accumulation (Figure 
4.9c). This points to the validity of the second possibility that in the absence of TS 
the misincorporation of FdUTP increases causing more DNA damage.  
In conclusion, we could not see any synergism between TS inhibition by RTXD and 
TS depletion by siRNA and NCS indicating that molecular reason for synergism 
observed between 5-FU with NCS is dependent not only on TS inhibition but also 
rely on the DNA and RNA damage induced by 5-FU. The fact that there was no γ-
H2AX accumulation 24 h post NCS treatment also indicates that TS inhibition alone 
is not sufficient to compromise the HRR as was observed with 5-FU. The activation 
of DNA damage response and γ-H2AX accumulation in TS depleted cells treated 
with 5-FU is surprising but as described earlier could be the result of increased 
misincorporation of the FdUTP.  
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Figure 4.9 Depletion of TS using siRNA or pharmacological inhibition does not 
synergize with NCS.  
(a) & (b) SW480 cells were depleted of thymidylate synthetase (TS) using siRNA mediated 
transfections. 16 h post transfections, cells were treated with 5-FU or NCS for 24 h 
respectively. Cells were harvested and lysates were analyzed by immunoblotting using the 
indicated antibodies. (c) SW480 cells were treated with Raltitrexed (RTXD) for 24 h followed 
by 100 ng/ml NCS for 24 h. Cells were fixed, stained for γ-H2AX and fluorescence intensity 
quantified as described in section 3.4. The γ-H2AX intensities were plotted as boxplots.   
Scr-Scrambled siRNA. TS-Thymidylate synthetase. 
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4.10 MK2 knock down does not rescue SW480 cells from the effects of 5-
FU 
Mitogen activated protein kinase- activated protein kinase 2 (MK2) was recently shown to 
reduce the γ-H2AX accumulation in response to gemcitabine, another nucleoside 
analog used in cancer treatment (Köpper et al., 2013). We asked if MK2 depletion or 
inhibition could have a similar effect on 5-FU induced DNA damage. The reason 
behind this assumption was that both these nucleoside analogues are capable of 
misincorporation in DNA and we wanted to know if MK2 expression can be 
correlated to the outcome of 5-FU treatment.  
To this end, we depleted MK2 in cells using siRNA and treated them with 5-FU. The 
immunoblotting showed that there was no rescue in terms of γ-H2AX level reduction 
as reported for gemcitabine (Figure 4.10 a). We had used two different 5-FU 
concentrations namely, 100 µM and 5 µM to see if the extent of DNA damage 
induced may dictate the involvement of MK2. But in neither case did we see any 
significant effect of MK2 depletion and this gave us a hint that MK2 cannot rescue 
the cells from the effects of 5-FU induced DNA damage.  
We next performed cell proliferation assays that showed no significant increase of 
cell proliferation in cells treated with a combination of MK2 inhibitor and 5-FU (Figure 
4.10 b). Additionally, the DNA damage induced by NCS alone was also not 
significantly altered by the presence of MK2 inhibitor (Figure 4.10a) and the effect on 
cell proliferation was also not drastic in NCS treated cells (Figure 4.10 c). Similarly, 
MK2 did not show any rescue effect in cells treated with 5-FU in combination with 
NCS. These observations led us to conclude that MK2 does not participate in 5-FU 
induced DNA damage like it does for gemcitabine induced DNA damage. This also 
means that the expression of MK2 may not play a significant role in deciding the fate 
of 5-FU based regimens.  
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Figure 4.10 5-FU induced DNA damage is not rescued by MK2 inhibition. 
MK2 was either depleted using siRNA or using a pharmacological inhibitor (MKi) in SW480 
cells.  (a) Cells treated with 5-FU for 24 h. (b) Cells treated with 5-FU/DMSO with or without 
MK2 inhibitor for 24 h followed by NCS for 24 h (c) cells treated with 100 ng/ml NCS for 24 h 
with or without MK2 inhibitor, cell confluency was measured every day using cyntellect 
celigoTM. See section 3.1.10 for method (d) Cells depleted of MK2 were treated with 5-
FU/DMSO for 24 h followed by treatment with 100 ng/ml NCS for 24 h, the samples were 
harvested and whole cell lysates analyzed by immunoblotting using the indicated antibodies. 
 
4.11 Gemcitabine also leads to accumulation of γ-H2AX but is 
accompanied with apoptosis in SW480 cells 
Since it is known that 5-FU as well as gemcitabine disrupt the nucleotide pools (see 
section 1.4.4), we next investigated if the treatment of colorectal cancer cells with 
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gemcitabine would produce similar effects as 5-FU in synergizing with NCS. The 
question we addressed was, is 5-FU unique in reducing the HRR or do other 
nucleoside analogues like gemcitabine that also effect the nucleotide pools also able 
to show similar behavior? 
We investigated the accumulation of γ-H2AX using immunoblotting and quantitative 
immunofluorescence. We found that gemcitabine, at concentrations of 100 nM 
caused accumulation of γ-H2AX in SW480 cells albeit with accompanying apoptosis, 
as confirmed by the presence of cleaved Caspase 3. This meant the source of γ-
H2AX could not be attributed to DDR alone as apoptosis also leads to γ-H2AX 
accumulation.  
In order to avoid the interference of apoptosis in the accumulation of γ-H2AX, we 
used ZVAD-FMK, a pan-caspase inhibitor. Here, we observed persistent γ-H2AX, in 
the immunoblots, with gemcitabine without any apoptosis however we did not find 
any synergism with NCS (Figure 4.11a). In fact, gemcitabine alone was able to 
induce large accumulation of γ-H2AX indicating that the SW480 cells are very 
sensitive to gemcitabine.  
We speculated that gemcitabine at this concentration (100 nM) was capable of 
overwhelming cells repair machinery which led us to perform titrations to look for 
concentrations at which synergisms with NCS could be possible. To our surprise, 
even at a broad range of gemcitabine concentrations (500-5 nM) we did not find any 
synergism with NCS (Figure 4.11d).  
We next performed cell proliferation assay to assess the effect of gemcitabine on 
rate of cell proliferation. At 100 nM gemcitabine concentration we observed acute 
cytotoxicity but could not attribute this cell death to synergism with NCS (Figure 
4.11c). At a lower concentration of gemcitabine (10 nM) there was some reduction in 
proliferation with NCS but here too the synergistic effect was missing. At 5 nM 
gemcitabine concentration there was no effect on cell proliferation with or without 
NCS (Figure 4.11b). We therefore concluded that gemcitabine does not synergize 
with NCS at various concentrations tested in this study in SW480 cells. As there was 
no synergism observed between gemcitabine and NCS we could not see any effect 
on persistence of γ-H2AX as gemcitabine alone was able to induce equal amount of 
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DNA damage as in combination with NCS. Therefore in the scope of current studies 
we could not conclude the effect of gemcitabine on HRR in SW480 cells.    
 
Figure 4.11 Gemcitabine exhibits concentration dependent cytotoxicity but does not 
synergize with NCS.  
SW480 cells were treated with 100 nM gemcitabine for 24 h followed by NCS for 24 h. 
ZVAD was added to prevent apoptosis. Cells were harvested and whole cell lysates were 
analyzed by immunoblotting using the indicated antibodies.(b) SW480 cells were treated 
with 5 and 10 nM gemcitabine for 24 h followed by treatment with NCS for 24 h.  (c) SW480 
cells were treated with 100 nM gemcitabine on day 1 and 100 ng/ml NCS on day2. 
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Measurements were made at 24 h intervals using cyntellect celigoTM as described in section 
3.1.10. (d) SW480 cells were treated with indicated gemcitabine concentrations (500 nM to 5 
nM) for 24 h followed by 100 ng/ml NCS for 24 h. The cells were fixed and stained for γ-
H2AX as described in section 3.4. Automated microscopy and image analysis was 
performed using BD pathwayTM system and results shown as box plot (n=3).  
 
4.12 Ribonucleotide supplementation does not rescue gemcitabine 
treated cells 
As earlier with 5-FU (Figure 4.7), we then investigated if the DNA damage induced 
by gemcitabine could be overcome by supplementing ribonucleotides as was 
observed with 5-FU (Figure 4.9). To this end we supplemented SW480 cells with 
300 mM each of all the four ribonucleotides. The idea was that if the treatment of 
gemcitabine completely inhibited the function of RR, the supplementation of 
ribonucleotides should not have any effect on the DNA damage repair. Expectedly, 
supplementation of gemcitabine treated cells with ribonucleotides did not reduce γ-
H2AX levels (Figure 4.12). This was so because gemcitabine had already 
compromised the ability of cells to produce deoxynucleotides from ribonucleotides 
indicating absolute inhibition of RR. Not surprisingly, DDR was not attenuated either 
as seen by the high levels of phosphorylated Chk2. In comparison, 5-FU induced 
DNA damage and DDR could be effectively attenuated by ribonucleotide 
supplementation. In conclusion, ribonucleotide supplementation rescued 5-FU 
treated cells but not gemcitabine treated cells indicating that RR inhibition by 
gemcitabine is absolute in SW480 cells at a concentration of 100 nM gemcitabine.  
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Figure 4.12 Ribonucleotide supplementation does not rescue gemcitabine treated 
cells.  
SW480 cells were treated with 5 µM 5-FU/100 nM gemcitabine/DMSO for 24 h followed by 
1X ribonucleotides and/or 100 ng/ml NCS for 24 h. Samples were harvested and whole cell 
lysates were analyzed by immunoblotting using the indicated antibodies. Antibodies to γ-
H2AX were used to quantify the extent of the DNA damage response, pChk2 was used to 
check for activation of DNA double strand break signaling, whereas β-actin was detected as 
a loading control. 
 
4.13 HU induced ribonucleotide reductase inhibition or depletion of 
RRM2 does not synergize with NCS in SW480 cells 
We next questioned, what would be the effect of specifically inhibiting ribonucleotide 
reductase (RR) on γ-H2AX persistence in SW480 ceIls? This was of interest as 
inhibiting or depleting RR would cause disruptions in nucleotide pools. As shown 
earlier, disruption of nucleotide pools along with DNA and RNA damage inducing 
properties of 5-FU are responsible for the reduction in HRR, we therefore asked, 
does the inhibition of RR also would cause persistent γ-H2AX. Gemcitabine, apart 
from inhibiting RR also causes termination of DNA synthesis (section 1.4.4) 
therefore the extent of the role of RR cannot be clearly understood. In order to probe 
the role of RR in DNA damage repair, we used a specific RR inhibitor, hydroxyurea 
(HU). SW480 cells treated with 1 mM HU showed a large accumulation of γ-H2AX, 
but this was accompanied by apoptosis as was confirmed by the presence of  
cleaved PARP and cleaved caspase 3 (Figure 4.13a). We therefore concluded that 
HU is lethal to SW480 cells and therefore not suitable for continuing the studies on 
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RR inhibition and studying the effects of RR inhibition on persistent γ-H2AX and later 
the effect on HRR.  
Since the inhibition of RR by HU was lethal to CRC cells, we decided to deplete RR 
from cells using siRNA. RR functions as a heterodimeric tetramer consisting of a 
large RRM1 and a smaller RRM2 subunit. We targeted the RRM2 using siRNA and 
depleting the cells of RRM2 led to the accumulation of γ-H2AX (Figure 4-13 b and c) 
indicating the stress induced by the depletion. Combining the knockdown of RRM2 
with NCS induced higher γ-H2AX accumulation though there was no synergism 
between RR inactivity and (Figure 4.13c). This suggested that no significant 
radiosensitization is achieved upon depletion of RRM2 in CRC cells. 5-FU in RRM2 
depleted cells caused an increase in the γ-H2AX levels but this was additive in 
nature and not synergistic. Further, depleting the cells of RRM2 did not cause 
activation of Chk2 but its combination with 5-FU resulted in additive effect on Chk2 
activation. 
In conclusion, hydroxyurea is too toxic even at small concentrations to show 
synergism with NCS. Depletion of RRM2 shows some additive effects with NCS but 
no synergism and RRM2 depletion with 5-FU (5 µM) treatment also show additive 
effects which may be attributed to their individual effects. Taken together, inhibition 
of RR by a specific inhibitor HU could not be used to confirm the effect of RR 
inhibition on the persistent γ-H2AX while the depletion of RRM2 by siRNA indicates 
that there is some additive effect but no effect on persistence of γ-H2AX. This 
therefore indicates that RR inhibition or depletion in combination with NCS does not 
synergize to produce persistent γ-H2AX. The large γ-H2AX levels seen upon 
inhibition or depletion of RR or its components indicate that the cells are stressed 
and incur DNA damage but this is independent of the NCS treatment. The 
combination of 5-FU with RR depletion also does not produce any synergisms 
indicating that the γ-H2AX observed is from the additive effect.  
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Figure 4.13 Ribonuleotide reductase inhibition or depletion of RRM2 causes DNA 
damage but does not synergize with NCS.  
(a) SW480 cells were treated with 1 mM HU for 24 h followed by 100 ng/ml NCS for 2 or 24 
h. (b) SW480 cells were depleted of the cellular RRM2 using siRNA mediated knockdowns 
SW480 cells treated with 100 ng/ml NCS for 24 h. (c) SW480 cells were depleted of the 
cellular RRM2 using siRNA mediated knockdowns. The cells were treated with 5-FU for 24 
h. Samples were harvested and whole cell lysates were analyzed by immunoblotting using 
the indicated antibodies. β-actin/ Hsc70 staining served as a loading control.  
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4.14 Antagonizing HRR also results in persistent γH2AX in SW480 cells 
HRR is an essential component of DNA repair in cells, and it has been shown that 
targeting this machinery can cause radiosensitization. Based on our earlier 
observation that 5-FU reduces HRR, we next investigated if inhibition of HRR would 
give a similar phenotype as 5-FU, i.e. persistent γ-H2AX. This experiment could 
elucidate if the inhibition of HRR produces persistent γ-H2AX, further incriminating 5-
FU as an agent that inhibits HRR. 
To this end, we employed a newly discovered Rad51 inhibitor B02, to inhibit the 
HRR. Treatment with 10 mM B02 alone was sufficient to cause accumulation of γ-
H2AX though this was accompanied by apoptosis, confirmed by the presence of 
cleaved PARP and cleaved caspase 3 (Figure 4.14). Upon inhibition of apoptosis 
with 20 µM ZVAD-FMK, B02 did not show any significant γ-H2AX accumulation, thus 
confirming that γ-H2AX accumulation seen with B02 was due to apoptosis. B02 in 
combination with NCS led to persistent γ-H2AX similar to 5-FU in combination with 
NCS. This observation further affirms our hypothesis that 5-FU affects the efficiency 
with which CRC cells perform the HRR.  
 
 
Figure 4.14 Inhibition of HRR by Rad51 inhibitor also causes persistent γ-H2AX. 
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SW480 cells were treated with 5 µM 5-FU\DMSO\ 10 mM B02 for 24 h followed by NCS 
and/or 20 µM ZVAD for 24 h. The samples were harvested and analyzed by immunoblotting 
using the indicated antibodies. Antibodies to γ-H2AX were used to quantify the extent of the 
DNA damage response, antibodies to cleaved caspase 3 and cleaved PARP were used to 
quantify the extent of apoptosis. β-actin staining served as a loading control.  
 
4.15 Investigating the role of mismatch repair system 
The role of MMR in the context of 5-FU has been extensively studied (Jiricny et al, 
2006) and it has been speculated to act upstream of HRR (Mohindra et al., 2002) as 
its regulator. Acknowledging the role of MMR in 5-FU induced DNA damage, we 
studied the possible interaction between HRR and MMR in our treatments. Two of 
the important components of the MMR system are MLH1 and MSH2 (section 1.10). 
With this background, we wanted to know if MMR inhibition reduces the efficiency of 
HRR. For this purpose we again used persistent γ-H2AX as readout (γ-H2AX 
observed 24 h post-NCS treatment) for DNA damage and effect on HRR.  
To investigate the role of MMR as a regulator of HRR, we depleted SW480 cells of 
MLH1 and MSH2 and analyzed the samples using immunoblotting. Depletion of 
MLH1 and MSH2 in combination with NCS did not show any effect on the 
accumulation of γ-H2AX (Figure 4-16a & 16b). Absence of apoptosis was confirmed 
from the lack of cleaved PARP, indicating that the γ-H2AX levels were solely due to 
DNA damage and not due to apoptosis. However, 5-FU treatment in MLH1 and 
MSH2 depleted cells increased γ-H2AX levels moderately but was not convincing to 
confirm synergistic effect. This was expected as MMR plays a critical role in 
identifying and repairing the damage induced by 5-FU. Therefore lack of MSH2 or 
MLH1 will render cells incapable of detecting and repairing the DNA damage 
induced by 5-FU alone which may be a cause for increased γ-H2AX in cells.  
Interestingly, we also observed an increase in total Rad51 levels in response to both 
NCS and 5-FU but the differences could not be attributed to MLH1 depletion. This 
may indicate cells attempt to repair the damaged DNA, but because we do not see a 
corresponding reduction in γ-H2AX levels it is hard to predict what this increased 
Rad51 levels mean.   
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These results indicate that MMR may play only a minor role in HRR though depleting 
SW480 cells of the components of MMR slightly increased the DNA damaging 
activity of 5-FU. This therefore means that the presence or absence of MMR may not 
affect the HRR itself but may have a greater effect on the treatment with 5-FU.   
 
Figure 4.15 Inhibition of MMR does not synergize with NCS or 5-FU. 
SW480 cells were depleted of (a) MLH1, (b) MSH2 for 16 h and treated with DMSO/5-FU for 
24 h followed by NCS for 24 h. Samples were harvested and whole cell lysates analyzed by 
immunoblotting. Antibodies to γ-H2AX were used to quantify the extent of the DNA damage 
response, whereas Hsc70 was detected as a loading control.   
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5 Discussion 
5.1 Do nucleoside analogs induce γ-H2AX accumulation?  
Nucleoside analogs induce DNA damage by misincorporation into DNA. BER has 
been shown to recognize 5-FU induced DNA damage and during the repair, ssDNA 
is generated as an intermediate (Wyatt and Wilson, 2009). 5-FU induces both 
ssDNA and dsDNA breaks in SW620 cells (Matuo et al., 2009); however, higher 5-
FU concentrations were used (15.4 µM vs 5 µM).  In this study, γ-H2AX is observed 
12 h after 5-FU treatment and coincides with apoptosis, which makes it difficult to 
identify the cause of γ-H2AX accumulation, but at lower concentrations of 5-FU (1 
µM) γ-H2AX is not observed.  5-FU treatment for 24 h shows γ-H2AX accumulation 
in TE11 (Esophageal squamous cell carcinoma) cells but not in TE1 cells 
(Sakogawa et al., 2013). Similarly, 5-FU treatment causes γ-H2AX accumulation in 
Ishikawa cells (endometeroid adenocarcinoma cell line) but not in HEC-1A and HEC-
1B, though high γ-H2AX levels are attributed to 5-FU induced apoptosis (Ikeda et al., 
2000). Treatment with 15 µM 5-FU for 18 h causes increase in γ-H2AX levels in HCT 
116 cells (Urick et al., 2011).  
We also observe that 5-FU at lower concentrations (5 µM) did not induce γ-H2AX 
accumulation while at higher concentrations (100 µM) there is a significant 
accumulation of γ-H2AX but it is accompanied with apoptosis. Therefore, 5-FU 
induced γ-H2AX accumulation appears to be both concentration and cell line 
dependent. 
Gemcitabine, another nucleoside analog has been shown to induce γ-H2AX in ML1 
(Thyroid tumor cells) cells at very low concentrations (10 nM) but at higher 
concentrations (100 nM) the γ-H2AX foci formation is quicker (foci formed in 2 h). 
Interestingly, at both concentrations and at 24 h post gemcitabine treatment the 
number of γ-H2AX positive foci remained the same. γ-H2AX foci are also induced in 
gemcitabine treated U2OS cells  and Ara-C treated LoVo cells (Köpper et al., 2013). 
We also observe γ-H2AX accumulation and foci formation in gemcitabine treated 
SW480 cells. However, the γ-H2AX intensities quantified in gemcitabine treated cells 
are concentration dependent, with higher concentrations causing more damage 
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(Figure 4.11d). It therefore appears that gemcitabine induces the γ-H2AX foci in a 
variety of cell lines and at different concentrations although we observe that the 
extent of γ-H2AX accumulation is dependent on the concentration at least in SW480 
cells.  
We observe gemcitabine induces DNA damage even at very low concentrations 
whereas 5-FU needs relatively higher concentration to induce DNA damage. At the 
same time, we observe synergism between 5-FU and NCS (Figure 4.1) whereas 
gemcitabine and NCS do not synergize (Figure 4.11 a-d). The apparent difference in 
the observations with 5-FU and gemcitabine can be attributed to different 
mechanism of action of these two drugs. 5-FU misincorporation does not stop DNA 
polymerase from replicating DNA, while two adjacent gemcitabine molecules in DNA 
stall the DNA replication. Gemcitabine induced extensive DNA damage in SW480 
cells indicate their sensitivity and the same also prevents the study of synergism with 
NCS. Both the drugs disrupt the nucleotide pools, though with different mechanisms, 
5-FU inhibits TS and reduces the available dTMP pools but gemcitabine inhibits RR 
and therefore deprives the cells of all the deoxyribonucleotides and this difference 
may account for gemcitabine induced severe DNA damage at low concentrations. 
The lack of synergism in gemcitabine treated SW480 cells at various concentrations 
may explain its limited success in colorectal cancer therapy.  
     
5.2 Does 5-FU treatment activate DNA damage response?  
We observe that treatment with 5-FU caused an activation of Chk1, Chk2 and 
accumulation of γ-H2AX indicating an activated DDR (Figure 4.1 and 4.7). It was 
shown that 5-FU treatment led to activation of Chk1 in HeLa and H1299 cells (Xiao 
et al., 2005) but not in HCT 116 p53 +/+ and HCT 116 p53 -/- cells. Surprisingly, 5-FU 
treatment does not induce the activation of Chk1, Chk2, ATM or γ-H2AX in HCT15 
cells, a proven 5-FU resistant cell line (Adamson et al., 2005). It could be due to the 
difference in metabolism of 5-FU in these cells. Nevertheless, it is clear that 5-FU 
induced activation of DDR is cell type specific and more importantly the components 
of the DDR getting activated are also cell type dependent.  
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This is important because the same drug is eliciting different responses in different 
cells and this information can be used to decide the efficacy of combination therapy. 
The dependence of DDR activation on cell lines is of clinical use, as cells that do not 
activate DDR may show very little response to the inhibitors of DDR proteins. 
Currently, Chk1 and Chk2 inhibitors are in clinical trials and can be used in 
combination with 5-FU for CRC therapy. In order to improve the efficacy of these 
new age inhibitors with 5-FU, knowledge of DDR activation is important.  
HCT 15 cells, which do not show DDR are also highly resistant to 5-FU; therefore 
patients having morphological features and expression pattern similar to HCT15 
should be treated with other drugs.  Interestingly, HCT 116 and HCT15 are MMR 
deficient cell lines, while the others including SW480 are MMR proficient, this 
testifies the importance of MMR in recognizing the DNA damage induced by 5-FU 
and activation of DDR. It has been reported that hMSH2 interacts with ATR providing 
a possible link between MMR and DDR (Wang and Qin, 2003).  
Overall, the effectiveness of treatment with 5-FU seems to be linked to the MMR 
status of cells. It can therefore be inferred that effectiveness of the treatment with 5-
FU depends on the MMR status of the cell line.  Interestingly, 70-85% of the CRC 
cell lines are derived from CIN pathway and therefore our studies with 5-FU and 
NCS and synergisms between them may be applied to the majority of the cases. Our 
observations further consolidate the knowledge on the effect of 5-FU and its relation 
to MMR system. Therefore, cancers derived from MSI pathway may not respond 
very well to chemoradiotherapy and at the same time 5-FU induced 
radiosensitization may also not be seen in these cells.  
5.3 Is persistent γ-H2AX a mark for irreparable DNA damage?  
The γ-H2AX foci remaining in the cells 24 h post NCS treatment are considered as 
persistent γ-H2AX. Persistent γ-H2AX foci are believed to indicate irreparable DNA 
damage and have been described both in vitro (Banath et al., 2010) and in vivo 
(Ahmed et al., 2012). MNNG (methylnitronitrosoguanidine) treated CHO and V79 
cells, and mitomycin C treated corneal endothelial cells C, also show persistent γ-
H2AX (Banáth et al., 2010). One reason for the persistence of γ-H2AX foci could be 
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that, extremely extensive DNA damage overwhelms the DNA repair machinery to 
such an extent that the rate of repair cannot keep up with activation of apoptotic 
mechanisms, leading to cell death. In support of this argument it was shown 
exposure to γ-radiation of DNA repair deficient CHO cells leads to persistent γ-
H2AX, linking the deficient repair to the persistent γ-H2AX (Kato et al., 2008).  
The other possibility for the persistence of γ-H2AX is the failure to dephosphorylate it 
upon completion of the repair. WIP1 (Wild type p53 induced phosphatase 1) 
phosphatase was shown to dephosphorylate γ-H2AX after DNA repair and depletion 
of WIP1 causes persistent γ-H2AX (Nguyen et al., 2010). SW480 cells or HeLa cells 
do not harbor any mutation in this gene and we observed that the m-RNA levels of 
WIP1 did not change after the treatment.  
Oxidative stress was also shown to cause persistent γ-H2AX though the molecular 
details for this are not known but a general hypothesis is that it could be a result of 
ROS mediated DNA damage (Tanaka et al., 2006). Neither 5-FU nor NCS have 
been reported to cause oxidative stress.  We observe persistent γ-H2AX in cells 
treated with 5-FU and NCS together, whereas the single treatments do not induce 
this persistence. As described above the SW480 and HeLa cells do not have any 
mutation in the WIP1; however, SW480 cells have a mutant p53 and HeLa cells do 
not express p53, but WIP1 expression was observed in a variety of p53 mutant 
cancer cell lines (Park et al., 2012).  
Therefore the lack of WIP1 protein expression can be ruled out as a reason for the 
persistent γ-H2AX observed in SW480 and the HeLa cells. The only remaining 
hypothesis to explain the persistent γ-H2AX in the 5-FU and NCS treated cells was 
inhibition of the repair pathways, and in accordance with this hypothesis we find that 
5-FU reduces the HRR but not the NHEJ. Thus, we attribute suboptimal HRR 
efficiency as the molecular reason for the persistence of the γ-H2AX in 5-FU 
pretreated cells combined with NCS.  
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5.4 Resistance to 5-FU and apoptosis 
HCT 116 have been reported to be very sensitive to 5-FU while SW620 and SW480 
are resistant (Borralho et al., 2007). Recent classification of several CRC cell lines, 
based on the GI50 values places SW480 (6.36 µM) and SW620 (17.23 µM) in the 
category of resistant cell lines. For comparison, this scale ranges from 0.03 µM for 
HDC73 (indicating most inhibited) to 47.5 µM for HT15 (indicating least inhibited) 
(Bracht et al., 2010). The IC50 values for the SW480 and SW620 calculated were 
17.5 µM (Nita et al., 1998) and 15.3 µM (Mans et al., 1999) respectively. One study 
claims IC50 for HT-29 as 19.3 µM and SW480 as 17.5 µM (Nita et al., 1998) , 
whereas another study puts these values at 0.66 µM for HT-29 and 2.75 µM for 
SW480 (Violette et al., 2002b). 
 There are obvious differences in IC50 values in these reports, though overall, all the 
studies indicate that SW480 cells are intermediate- to- resistant for 5-FU. This 
implies that our studies are done in a background of resistant cell lines and can be 
extrapolated to other 5-FU resistant cell lines. This observation gains importance in 
the backdrop of the fact that 5-FU resistance in patients is a common phenomenon 
and a serious threat to disease free survival.  
One of the reasons for these apparently contradictory studies on 5-FU resistance is 
the lack of complete understanding about the molecular mechanisms leading to 
resistance. Resistance towards 5-FU can be acquired by either evading apoptosis or 
overexpression of TS. Recently, attempts have been made to understand the 
molecular reasons behind 5-FU induced apoptosis. Contin B and Contin D, two 5-FU 
resistant cell lines derived from HCT 116 show marked reduction in apoptosis in 
response to 5-FU, though the 5-FU misincorporation in DNA is not reduced, 
indicating that  5-FU induced apoptosis and DNA damage are not coupled (Paolucci 
et al., 2006). We observe that 5-FU (5 µM) treated SW480 cells do not show 
persistent γ-H2AX or impaired cell proliferation and apoptosis (Figure 4.1 and 4.3). 
This again showcases that SW480 cells are resistant to 5-FU and the fact that 
apoptosis is not induced in these cells in response to 5-FU indicates that γ-H2AX 
accumulation is solely dependent on DDR. Furthermore, 5-FU sensitizes SW480 
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cells to NCS but we do not observe immediate apoptosis confirmed by the absence 
of cleaved caspase 3 and cleaved PARP (Figure 4-15).    
However, 100 µM 5-FU induced apoptosis completely inhibits cell proliferation and 
leads to massive accumulation of γ-H2AX (Figure 4.3 and 4.9). This signifies that 
apoptotic machinery is not inactivated in resistant cell and this tolerance can be 
overcome by sufficiently high doses of 5-FU.   
It has also been reported that in CRC cell lines, chemosenstivity depends on Bcl-XL 
to Bak ratio. Further, 5-FU causes 6 fold induction in the expression of Bax, and 
depleting cells of Fas reduces apoptosis (Borralho et al., 2007) . An attempt to 
classify resistant CRC cell lines based on the expression of pro- and anti-apoptotic 
proteins has also not been very successful so far and SW480 cells did not show any 
correlation between pro and anti-apoptotic proteins (Violette et al., 2002a). 
Therefore, induction of apoptosis in response to 5-FU, though signifies cell death, 
apparently the correlation between pro- and anti-apoptotic proteins and resistance is 
not clear. Investigation of multiple pathways may hold the key to decipher 5-FU 
resistance in CRC cells and may also allow us to better target the resistance cells.   
NCS concentrations above 20 nM have been shown to severely impair cell 
proliferation in human cervical cancer cell lines (Bañuelos et al., 2003). Similarly, 
exposure of HCT 116, SW480, RKO and Colo 320 cells to 10 Gy radiation blocks 
cell proliferation and leads to cell death (van Engeland et al., 2011). We find that 
100ng/ml NCS, which correlates to 5 Gy of radiation, does not show any effect on 
the cell proliferation (Figure 4.3); however, combination of 5-FU and NCS severely 
impairs cell proliferation.  
It is possible that the SW480 cell lines are more resistant to γ-radiation and NCS 
compared to the cervical cancer cell lines. We did not try NCS concentrations 
equivalent to 10 Gy or more on SW480 cells, and therefore cannot agree or disagree 
with this report. However, our observation that 5-FU is lethal to HT-29 cells at a 
concentration of 5 µM agrees with some studies (Lamberti et al., 2012) but is in 
contradiction with others, signifying variability in the expression landscape of the 
available intra- and inter-cancer cell lines.   
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Gemcitabine is a radiosensitizer in pancreatic cancer, lung cancer, head and neck 
cancer and HT-29 cell lines though we did not see any synergistic effect of 
gemcitabine with NCS (Shewach and Lawrence, 1996a). Interestingly, gemcitabine 
alone was sufficient to induce extensive DNA damage that lead to apoptosis and this 
made it difficult to assign the source of γ-H2AX accumulation. Inhibition of apoptosis 
also lead to similar γ-H2AX accumulation indicating that gemcitabine induced DNA 
damage is responsible for γ-H2AX accumulation (Figure 4.11a and 4.11d).  
However, there is some effect of the combination at a concentration of 10 nM on cell 
proliferation but this is not significant enough to be classified as synergistic effect 
(Figure 4.11b and 4.11c). Surprisingly, no synergistic effect was observed in terms of 
γ-H2AX accumulation at 10 nM gemcitabine concentration (Figure 4.11d). Therefore, 
the initial lag in cell proliferation at low concentrations is overcome by the SW480 
cells. The fact that synergism between gemcitabine and NCS is not observed even 
at a concentration of 5 nM indicates that gemcitabine may not produce encouraging 
results in CRC therapy and in line with our observations, gemcitabine based clinical 
trials have shown modest benefits to CRC patients.   The difference in the response 
to gemcitabine can be attributed to different cell lines in ours and the indicated study.  
 
5.5 Does inhibition of double strand break repair sensitize cells to 
NCS/radiation?   
Many compounds have been described that affect DSB repair processes like 17-
AAG, an HSP90 inhibitor inhibits HRR (Kobayashi et al., 2005) and reduces the total 
Rad51 levels to radiosensitize HT-29 and EOC (ovarian cancer) (Choi et al., 2014). 
Similarly, persistent γ-H2AX and reduction of DNA repair occurs in 17DMAG treated 
MiaPaCa cells (Dote et al., 2006).  Rad51 foci formation was reportedly affected in 
gemcitabine treated V79 cells, however this report concludes that gemcitabine 
affects only large foci formation and not all foci (Floris et al., 2003). Moreover, 
DRGFP assay performed in gemcitabine treated MiaPaCa cells does not show 
reduction of HRR (Morgan et al., 2010).  
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It has been reported that Chk1 phosphorylates Thr309 of Rad51 which facilitates its 
recruitment to the chromatin (Sorensen et al., 2005). Furthermore, AZD7762, a 
Chk1inhibitor prevents Rad51 foci formation and leads to persistent γ-H2AX in 
MiaPaCa-2 cells (Morgan et al., 2010) . In light of the information that Chk1 inhibition 
reduces the HRR, it can be conceived that Chk1 inhibition would radiosensitze 5-FU 
resistant cells, but as stated earlier it is important to verify the activation of DDR 
proteins in resistant cell lines before moving ahead with targeting the DDR proteins.  
Hypersensitivity of BRCA2 deficient cell line, Capan-1 has been attributed to 
impaired Rad51 foci formation and BRCA1 defective breast cancer cells were found 
to be very sensitive to PARP inhibitors (McCabe et al., 2005; Rottenberg et al., 
2008). We observe that 5-FU inhibits HRR (Figure 4.4) and HRR deficient cells were 
shown to be hypersensitive to PARP inhibitors. PARP inhibitors are being 
investigated for the treatment of triple negative breast tumors harboring BRCA1/2 
mutations. Encouraging response rates were observed in phase I clinical trials of 
Olaparib and Paclitaxel (mitotic inhibitor), similarly, use of Olaparib in triple negative 
breast cancers, as a single agent has also yielded positive results.   
We, therefore, propose that combination of 5-FU and PARP inhibitors might be very 
effective in CRC therapy. However, in ovarian cancer cells, PARP inhibitors 
synergized with 5-FdUrD and not with 5-FU and similar results were obtained in 
esophegal cancer cell lines TE11 (Huehls et al., 2011; Sakogawa et al., 2013). 5-
FdUrD is a metabolite of 5-FU and it can be thought that metabolism of 5-FU may be 
different in these cancer cells. The fact that a metabolite of 5-FU synergizes with 
PARP inhibitors further strengthens our observations of 5-FU induced HRR inhibition 
and our proposal on the use of PARP inhibitors with 5-FU in CRC therapy.  
 
5.6 Why TS inhibition does not sensitize cells to NCS and why do 5-FU 
and RTX synergize in CRC cells?   
It has been shown that TS expression is inversely related to 5-FU and methotrexate 
response rates in patients (Cascinu et al., 1999). Interestingly, latter studies show 
that TS expression in primary tumors is higher compared to metastatic tumors and 
 Discussion 98 
that there is no correlation between TS expression and 5-FU response (Aschele et 
al., 2000).  Other studies; however, show that only TS expression is sufficient to 
predict 5-FU action (van Triest et al., 1999).  
Transient knockdown of TS reduces cell proliferation in HeLa cells and it therefore 
becomes apparent that the levels of TS is an important marker for deciding the 
action of 5-FU (Ferguson et al., 1999). We do not find any significant change in the 
total TS expression in tumors compared to the mucosa of patients (Figure 4.8). 
Surprisingly, TS expression remains unaffected in tumors and a variety of CRC cell 
lines (Amatori et al., 2006). It also supports other observations that expression of TS 
cannot be used to predict the response rates to chemotherapeutics (Aschele et al., 
2000) 
We employed pharmacological and siRNA mediated depletion of TS in our studies, 
For instance, shRNA depletion of TS induces radiosensitization in HCT116 and HT-
29 cells but siRNA mediated depletion of TS does not (Flanagan et al., 2012). It is 
difficult to explain this difference, though different methods of depletion may play a 
role. Our studies are in accordance with the study indicated above.  
RTX induced pharmacological TS inhibition increases γ-H2AX and RPA foci in HT-
29 and HeLa cells (Yang et al., 2008). RTX and γ-radiation synergize in clinical 
treatment and are used in neoadjuvant therapy. RTX fared better with γ-radiation    
than 5-FU in HT-29 and Scc 25 (head and neck cancer) cells, in reducing cell 
proliferation (Teicher et al., 1998). Surprisingly, TS depletion or pharmacological 
inhibition with RTX does not synergize with NCS in SW480 cells (Figure 4.9a and 
4.9c). Most likely, this is due to the variability in cellular resistance to 5-FU between 
ours and reported studies. This also explains as to why even at several (7nM - 700 
µM) RTX concentrations we did not see any synergism in SW480 cells.  
As stated earlier, one of the reason for 5-FU resistance is overexpression of TS, 
though we did not compare the expression levels of TS in different cell lines, it is 
conceivable that SW480 cells on account of being 5-FU resistant overexpress TS 
thus limiting the effect of RTX. Interestingly, our study also indicates that inhibition of 
TS alone may not sensitize the CRC cells. The fact that 5-FU sensitizes SW480 cells 
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to NCS and TS does not, can be used to speculate that, other activities of 5-FU 
which include DNA and RNA damage are crucial to radiosensitization, though we do 
not have any direct proof for it.         
5-FU and RTX in combination show synergistic effect in HCT-8 cells; this is 
surprising since both the drugs inhibit the same enzyme (Longo et al., 1998). One 
possible reason for this synergism is the different binding sites on TS, for RTX and 
5-FU.  Such a situation where the absence of the protein targeted by the drugs 
potentiates their efficacy is referred to as complementary lethality (Rytelewski et al., 
2013). It has been shown that, TS depletion along with 5-FUdR treatment causes 
complementary lethality (Rytelewski et al., 2013).  We also have similar observations 
with 5-FU and TS knockdown (Figure 4-9b) in terms of γ-H2AX accumulation but 
there was no significant increase in pChk2 levels.  
Taken together our results indicate that TS depletion by siRNA does not synergize 
with NCS while pharmacological inhibition shows additive effect with NCS but not 
synergistic. The observation that 5-FU synergizes with RTX is surprising, but it may 
be used in clinics to treat patients. So far RTX has been used as a substitute to 5-FU 
but our studies and similar other studies indicate that the use of 5-FU and RTX 
together may improve the efficacy of the regimen.  
 
5.7 Can gemcitabine be used as an alternative to 5-FU in CRC patients?  
Gemcitabine was reported to have modest effect on the response rates in CRC 
patients, though it reduced the locoregional recurrence in patients with advanced 
CRC in combination with γ-radiation (Allal et al., 2005; Salgado et al., 2013). In 
combination with capecitabine (oral 5-FU drug) it does not improve the response 
rates (Salgado et al., 2013). 
In our studies we did not see any synergism between gemcitabine and NCS which 
raises a significant question on the use of gemcitabine in CRC therapy. As stated 
earlier, it only has a modest effect on the outcome but interestingly no molecular 
reason has been implicated for the poor response to gemcitabine in CRC patients.   
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Gemcitabine has been shown to induce apoptosis in HCT 116 p53+/+and U2OS cells 
while no apoptosis is seen in HCT 116 p53 -/- and SaOS cells (Hill et al., 2013). This 
indicates that gemcitabine induces p53 dependent apoptosis. Furthermore, PUMA 
levels increase in response to gemcitabine, thus confirming the involvement of p53 
mediated apoptosis.  
SW480 cells harbor a mutant p53 and do not transcribe PUMA (Yu et al., 2001). 
Surprisingly, we observed apoptosis in SW480 cells and therefore this raises an 
interesting question of why do the SW480 cells undergo apoptosis in response to 
gemcitabine? Recently, it has been reported in HCT 116 and SW480 cells, that 
selenite induced stress leads to ROS mediated apoptosis in which FOXO3a and Bim 
play critical roles (Luo et al., 2008). Gemcitabine also induces ROS in MiaPaCa and 
Colo357 (Arora et al., 2013). This indicates that apoptosis seen in SW480 cells can 
be due to gemcitabine induced ROS generation leading to activation of FOXO3a. 
Though we observed increased apoptosis in SW480 cells, we do not see synergism 
with NCS (Figure 4.11a and 4.11d).  
Similarly, we do not see any synergism in cell growth inhibition between gemcitabine 
and NCS (Figure 4.11c). Interestingly, even in the absence of apoptosis gemcitabine 
did not synergize with NCS. Our findings suggest that gemcitabine cannot synergize 
with NCS in CRC cell lines; however, the mode of apoptosis induction by 
gemcitabine in p53 mutant CRC cell lines needs further studies.  
 
5.8 Why MK2 does not rescue 5-FU treated cells? 
It has been reported that MK2 is needed for preventing apoptosis in p53 deficient 
cells for instance MK2 also mediates radioresistance in Panc1, MiaPaCa2 and 
BxPC3 cell lines by phosphorylating ATDC (Reinhardt et al., 2007; Wang et al., 
2014).This indicates that cells depleted of MK2 should be more sensitive to NCS but 
we do not observe any effect of MK2 knockdown on NCS treatment either on cell 
proliferation or γ-H2AX accumulation (Figure 4.10a-d) this could be due to differing 
cell lines between our and the quoted study.  
 Discussion 101 
MK2 has also been reported to increase resistance to cisplatin in p53- deficient 
tumors indicating that the resistance to cisplatin is independent of p53 status 
(Morandell et al., 2013) and MK2 in combination with camptothecin does not show 
any effect on long term cell survival (Zhang et al., 2009).  
 p38/MK2/AATF pathway is the repressor of p53 dependent apoptosis and this 
indicates that inhibition of p38 pathway might be a viable option for CRC therapy. 
However, it is also known that curcumin dependent increase in ROS levels facilitate 
apoptosis and has been shown in colo205 cells. Studies indicate that MK2 increases 
the ROS level which could argue that it might facilitate apoptosis, though this was 
not stated in the studies (Kobayashi et al., 2012). 
It has been shown that MK2 depletion attenuates DDR and decreases γ-H2AX in 
response to gemcitabine induced DNA damage (Köpper et al., 2013). Also, MK2 
knock down effectively rescues these cells and improves their proliferation. 
However, we did not see any effect of MK2 depletion or pharmacological inhibition 
on cell proliferation or reduction in γ-H2AX. This variation is most likely due to 
cellular variability and ensuing stress response.  
Further, as discussed earlier, differing mechanisms of 5-FU and gemcitabine action 
might also contribute to this observation. Gemcitabine addition in DNA produces 
lesions that cannot be read by DNA polymerase leading to DNA fork stalls. It has 
been speculated that MK2 depletion allows the recruitment of translesion 
polymerases that overlook the lesions and continue the DNA replication. In the case 
of 5-FU, such DNA lesions are not formed and so far the translesion polymerases 
have not been implicated in overcoming 5-FU induced replication fork stalls. As 
predicted, MK2 may play an important part in translesion DNA synthesis and 
therefore may rescue the gemcitabine treated cells. 5-FU treated cells on the other 
hand may not employ translesion synthesis and therefore depletion of MK2 may not 
rescue these cells. Therefore, it becomes evident that the involvement of MK2 
strongly depends on cell type and drug being used. 
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5.9 Summary and future perspectives 
Protecting the integrity of information in DNA is a big challenge for cells exposed to 
various chemical and physical agents. Nucleoside analogs represent one of many 
different chemotherapeutics that induce DNA damage and are the mainstay in 
treatment of a variety of cancers like 5-FU in CRC, gemcitabine in pancreatic cancer. 
They have been used in the clinics for a long time, however many questions 
regarding the action of the nucleoside analogs remain unanswered. One of the 
frequently asked questions is how to improve the efficacy of the nucleoside analogs? 
With poor response rates in the clinics necessitate this study. Nucleoside analogs 
are known to radiosensitize tumor cells but the mechanisms underlying this effect 
are poorly understood. Similarly, the resistance of tumors to chemotherapeutics is a 
well-known phenomenon in cancer treatment. The current study aims at 
understanding the molecular mechanisms behind 5-FU induced radiosensitization 
and finding novel pathways to selectively target cancer cells.  
Our study indicates that 5-FU pretreatment in combination with NCS results in 
persistent γ-H2AX in CRC cell lines, which is a result of reduced DNA repair. We 
further prove that, 5-FU inhibits HRR while unaffecting the NHEJ and this could 
explain the molecular reason behind the 5-FU induced radiosensitization. 5-FU 
inhibits TS and disrupts the nucleotide pools; we therefore reasoned that the 
reduction in HRR could be a consequence of TS inhibition.  
We next performed ribonucleotide supplementation and found that the disruption of 
nucleotide pools was responsible for the persistent γ-H2AX. We then employed B02, 
an inhibitor of Rad51, to show that HRR inhibition leads to persistent γ-H2AX similar 
to 5-FU. Considering the fact that 5-FU resistance is frequently seen in clinics, our 
results provide the basis for targeting HRR to overcome the 5-FU resistance. As 
discussed earlier, breast tumors with defective HRR are hypersensitive to γ-
radiation, our study corroborates with this observation that, inhibition of HRR can be 
used as a therapeutic strategy to radiosensitize cells. It is also observed that HRR 
deficient breast tumors respond to PARP inhibitors, and we show that 5-FU inhibits 
HRR, this alludes to the fact that PARP inhibitors may be used in combination with 
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5-FU or may be introduced in 5-FU based regimens to improve the overall response 
rates in patients.  
5-FU resistance is a common clinical curse that dampens the treatment outcome, 
our study indicates that use of HRR inhibitors in such cases may re-sensitize the 
cells to radiation therapy. Unfortunately, only a few specific HRR inhibitors are 
available and they have a very high IC50 value, making them unfit for clinical use. 
There is a need for more intensive research to identify specific HRR inhibitors with 
low IC50 values, which can be translated to clinically useful drugs.  
Interestingly, depletion of TS or use of a TS inhibitor raltitrexed, did not synergize 
with NCS arguing that 5-FU induced radiosenstization does not depend on the TS 
inhibition alone. TS depletion did not exhibit synergism with NCS in inducing DNA 
damage, although combined treatment with 5-FU showed complementary lethality. 
This argues for the use of RTX with 5-FU and not as a substitute of 5-FU.  
Furthermore, we investigated the possible use of gemcitabine in CRC treatment and 
find that gemcitabine does not synergize with NCS to induce DNA damage in CRC 
cell lines.  Moreover, 5-FU synergizes with NCS to reduce the cell proliferation while 
gemcitabine does not, indicating that gemcitabine is not a good alternative to 5-FU in 
CRC therapy.  
RRM2 inhibition also does not show synergism with NCS, indicating that depletion or 
inhibition of RR may not be beneficial in CRC therapy. Similar observations have 
been made in clinical trials that indicate that, gemcitabine only modestly improves 
the response rates in patients, our study also indicates that single treatment with 
gemcitabine is able to produce almost the same amount of damage as in 
combination with NCS. However, it does indicate that RR is a key enzyme that may 
be targeted to achieve the desired cell death but it may not synergize with NCS or γ-
radiation. Identifying appropriate concentrations of RR specific inhibitors like HU may 
further improve the response rates.    
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Figure 5.1 A model for 5-FU induced HRR inhibition. 
Combined effect of 5-FU on DNA, RNA damage and TS inhibition leads to reduced HRR 
and radiosensitization. RTX mediated TS inhibition alone does not synergize with NCS, 
similarly, gemcitabine induced DNA damage and nucleotide pool disruption also does not 
synergize with NCS.  
 
MK2 is reported to reduce the γ-H2AX levels in gemcitabine treated U2OS cells, we 
therefore investigated the role of MK2 in 5-FU induced damage in SW480 cells and 
found that MK2 does not reduce the γ-H2AX levels or rescue the 5-FU and NCS 
treated cells. Interestingly, MK2 inhibitors have been shown to reduce the tumor size 
in combination with cisplatin. Our study indicates that using 5-FU in combination with 
MK2 inhibitors may not be beneficial to patients.  
MMR is a key component in identifying and repairing 5-FU induced DNA damage, 
and as described earlier, mutations in this pathway are associated with 
predisposition to CRC. Interestingly, this pathway has been speculated to be 
involved in HRR but its role in HRR is not clear. In order to elucidate its role in 
radiosensitization, we depleted cells of MSH2 and MLH1. We find that depletion of 
MMR components does not sensitize cells to NCS or 5-FU. This elucidates that 
though MMR participates in HRR, during strand invasion but its loss does not 
significantly hamper the process. It also suggests that in clinics the MMR status may 
not correlate with response to radiation therapy.   
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Finally, we propose a model, wherein 5-FU induced HRR inhibition can be attributed 
to depletion of nucleotide pools along with DNA and RNA damage. We believe that 
the reduction in HRR is responsible for the radiosensitzation and persistent γ-H2AX 
which then causes cell death via apoptosis. Gemcitabine also disrupts the nucleotide 
pools and induces DNA damage but did not sensitize cells to NCS. RTX inhibits TS, 
but even RTX did not synergize with NCS. Taken together the radiosensitization 
effect of 5-FU can be attributed to reduced HRR efficiency of cells as a result of 5-
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7.1 Plasmid maps of DRGFP, pCBASCE I.  
 
 
7.2 Compounds screened for synergistic activity with 5-FU 
Naturally secreted chemical compounds from soil microbes were tested for their 
synergistic activity with 5-FU. After the initial screen 10 compounds that modulated 
γ-H2AX were chosen for validation. (a) Compounds that increased γ-H2AX levels (b) 













Curriculum Vitae  
Upadhyayula Sai Srinivas 
Apartment 279, Philip Reis straβe 9, Goettingen, 37075, u.saisrinivas@gmail.com 
Education 
University of Göttingen, Germany 
Masters in Molecular Biology, IMPRS Molecular Biology 
Thesis ” NIPP1 and Wip1 two regulators of protein phosphorylation and 
their impact on DNA damage response” 
 
2009-2011 
University of Hyderabad, India 
M.Sc Biochemistry  
Passed with Distinction 
 
2007-2009 
Osmania University, India 
B.Sc (Biochemistry, Microbiology, Chemistry)  
Passed with Distinction 
 
2004-2007 
All India Senior School Certificate Examination 
Passed with Distinction 
 
2004 
All India Secondary School Certificate Examination  




Supervised 3 lab rotation students, supervised tutorials for IMPRS Molecular Biology 
students, supervised advanced PCR courses for PhD students from GGNB and IMPRS 
Molecular Biology students.    
 
 
 
 
